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POLYMETHYLMETHACRYLATE (PMMA) NANOSPHERES (η-TSBC)
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ABSTRACT
The high viscosity standard two-solution bone cements (STSBC) developed in our
laboratory exhibits several advantages over other commercial powder-liquid cement
formulations. However, the high monomer concentration, viscosity, and exothermal temperature
are considered a major limitation to the use of this material. Modified two-solution cements
containing cross-linked polymethylmethacrylate (PMMA) nanospheres (η-TSBC), as part of the
polymer phase, were fabricated as the first step for optimization of cement viscosity for
application of the material in the treatment of vertebral compression fractures using
vertebroplasty (VP) and kyphoplasty (KP). The η-TSBC exhibited reduced viscosity, lower
polymerization exotherm, and residual monomer in comparison to STSBC. Nevertheless, the ηTSBC lacks bioactivity and has no biologic potential to remodel or integrate into the surrounding
bone. Also, addition of radiopacifiers such as barium sulfate and zirconium dioxide is required
for fluoroscopy guided procedures and is known to be detrimental to the cement mechanical and
bioactive properties. In this sense, η-TSBCs containing strontium-substituted hydroxyapatite
(SrHA) microspheres have been developed in this study as a step towards improving bioactivity
of these cement formulations. Hydroxyapatite (HA) is a natural bone mineral component and
strontium is known to stimulate bone formation and acts as a good contrast agent. In addition to
this, recent studies (1-4) have shown that the antibacterial property of hydroxyapatite
nanoparticles improved after partial or complete substitution of calcium with strontium ions. The

goal of addition of SrHA microspheres into the η-TSBC formulation is to improve bioactivity by
allowing apatite formation on the cement surface that would in turn help making chemical bonds
with the HA in the surrounding bone, and also to impart radiopacity and antibacterial properties
without the need to incorporate any additional radio contrast or antibiotic filler material. The
addition of SrHA microspheres at different concentrations resulted in improving the apatite
forming ability of η-TSBCs. The antibacterial properties of η-TSBC containing SrHA
microspheres were investigated in vitro by culturing Escherichia coli (E.coli) K12/pRSH103
biofilm which resulted in reduced biofilm growth on the cement surfaces with increasing SrHA
concentration, indicating capability of bacterial inhibition. The addition of SrHA microspheres
resulted in a reduction of mechanical properties in comparison to η-TSBC, bringing these values
closer to the human cancellous bone. However, the mechanical properties were similar to the ηTSBC containing 20% wt/vol ZrO2 as a radiopacifier, indicating no further detrimental effect of
the SrHA addition on the η-TSBC properties while replacing ZrO2 in order to impart radiopacity
and improve bioactivity. These cements were observed to require further optimization to
improve interfacial bonding of the SrHA microspheres to the cement matrix for enhancement of
mechanical properties of the material. In summary, η-TSBCs containing SrHA microspheres
were developed exhibiting a combination of attractive properties and potential for additional
modification that will prolong the life and performance of arthroplasties and vertebral
augmentation.
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Chapter 1
______________________________________________________________________________
1

Introduction

Acrylic bone cements have been developed primarily for augmentation and fixation of
prostheses and total joint arthroplasties, in order to provide stabilization of the implant and
transfer of mechanical loads between the implant and bone. Osteoporosis is well known for
deteriorating the structural strength of bone and leading to stresses that exceed the strength
of vertebrae, resulting in osteoporosis-induced vertebral compression fractures (5). Lately,
bone cements have found applications in spinal applications for treating vertebral
compression fractures. Galibert and Deramond (6) first conceived the technique of
percutaneous vertebroplasty (VP) with polymethylmethacrylate (PMMA), as a
reinforcement procedure for treatment of vertebral compression fractures. The
vertebroplasty procedure involves direct injection of PMMA bone cement and a contrast
agent, typically barium sulfate, into fractured vertebral bodies using fluoroscopic guidance
(7). This procedure was designed to alleviate pain and stabilize fractured vertebral bodies
in patients suffering primarily from osteoporotic compression fractures and metastatic bone
diseases (8). Kyphoplasty (KP), another procedure to treat vertebral compression fractures,
was developed in the 1990’s (9)(10). The kyphoplasty procedure involves introduction of
an inflatable bone tamp into the compressed vertebral body in order to create a cavity in the
centrum of the vertebrae, with the intent to expand and restore the vertebral body to its
original height (10). The cavity created by this action is then filled with PMMA bone
cement to stabilize the vertebral body and restore the normal load transmission patterns
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from vertebrae to vertebrae (10). The desired properties of PMMA bone cement for VP/KP
procedures differ in comparison to the properties of PMMA cements used in total joint
arthroplasties, and are as follows: easy handling and injectability into the collapsed vertebral
body, high radiopacity, lower viscosity (not too low), longer setting times (~ 15 mins),
lower curing temperature, requisite mechanical properties (comparable to those of healthy
vertebral body), low cost, slower resorption rates, biocompatibility, and excellent
bioactivity (5, 7, 8).
Although PMMA is the most commonly used material for vertebral augmentation
procedures presently, there are certain concerns associated with its use in VP/KP
applications. PMMA exothermic reaction can cause thermal necrosis and burns to the
surrounding tissue (11). Suppression of cell growth, DNA synthesis and glucose
metabolism resulting in cytotoxicity has also been observed due to release of toxic monomer
and PMMA debris (11). PMMA is non-resorbable and has no biologic potential to remodel
or integrate with the surrounding bone tissue. The lack of bioactivity and osteoconductivity
of PMMA results in the loss of bonding between cement and bone (7). The differences in
the mechanical properties of PMMA filled vertebrae and the adjacent vertebral body leads to
adjacent vertebral fractures (5). Hence, significant interest by the orthopedic surgeons has
been expressed for developing bone cements capable of promoting bone regeneration or
integrating into the surrounding bone and having mechanical properties similar to
cancellous bone.
Biomaterial-associated infections are also not uncommon in orthopedic surgery. PMMA
like any other biomaterial is susceptible to infections caused by bacteria and
microorganisms (12). Over the past few decades, antibiotics have been incorporated in
2

PMMA bone cements in order to prevent and cure orthopedic implant infections (13).
PMMA comes in direct contact with bone, physiological fluids, and blood which results in
the formation of a conditioning film by plasma proteins (12). This conditioning film can
then allow microorganisms to adhere and form biofilms on the biomaterial surface.
Antibiotic-loaded bone cements essentially consist of PMMA matrix, radiopacifiers, and an
antibiotic such as gentamicin (14), tobramycin (15), or erythromycin (16). Ethell et al. (17)
incorporated ceftiofur, liquid and powder gentamicin, and amikacin antibiotics into PMMA
and hydroxyapatite (HA) cement and studied their elution characteristics. They found that
HA cement had greater elution of antibiotics than PMMA and the gentamicin- and
amikacin-loaded HA cement released bactericidal concentrations of antibiotic for at least 30
days. It has been believed that the antibiotic release from the bone cements is mainly a
surface phenomenon as the bulk of PMMA is essentially impermeable. In vitro studies by
Van de Belt et al. (18) also confirm that only a minor portion (5-8 %) of the gentamicin
incorporated in bone cements is eluted. However, there have also been theories favoring a
bulk diffusion model for antibiotic release rather than an exclusive surface release
mechanism. Recently, Van de Belt et al. (19) suggested that the initial release when the
antibiotic-loaded cement is exposed to a fluid is mainly a surface phenomenon, whereas
sustained release over several days is a bulk diffusion phenomenon. Moreover, antibiotic
cements have an optimum surface for bacterial colonization and prolonged exposure to
antibiotics can allow for bacterial resistance to be developed (20, 21). Van de Belt et al. (19)
reported that Staphylococcus Aureus (S. Aureus) biofilm formation was reduced on
gentamicin loaded cements as compared to unloaded cements, but only for a short duration
during the initial burst release of the antibiotic after which the bacterial strain developed

3

resistance against gentamicin. Also, when antibiotics are added to PMMA before mixing as
a prophylactic measure, they can affect the mechanical properties of the cured PMMA (13).
It has been shown in literature that adding different antibiotics to PMMA in quantities less
than 2 g per standard polymer packet does not adversely affect the mechanical properties,
although concentrations exceeding 2 g does weaken them (22, 23). Therefore there is an
urge for developing alternate filler materials that can impart antibacterial properties to bone
cements. Preliminary work by Guida et al. (4) has shown that incorporation of strontium and
fluoride into glass ionomer cements improved antibacterial properties of the cement, with
the bactericidal action of strontium being more significant than fluoride. However, the
mechanistic action of Sr2+ on bacteria is less well understood than that of silver (Ag) (24).
Little is currently known with respect to bacterial resistance to strontium, due to limited
number of published studies on the in vitro or in vivo antibacterial applications of the ion.
To this effect, the focus of our work was to develop a bioactive and antibacterial twosolution bone cement based on strontium-containing hydroxyapatite (SrHA) that could be
used primarily for VP/KP as well as other applications.
Acrylic polymethylmethacrylate (PMMA) bone cement is currently the only material
used for augmentation and anchoring of total joint arthroplasties (25, 26). Most commercial
bone cements are available in powder-liquid formulations. The powder consists of PMMA
polymer, radiopacifier and initiator such as benzoyl peroxide, whereas the liquid component
consists of monomer methylmethacrylate (MMA) and an activator (e.g. N,N-dimethyl ptoluidine (DMPT)) (25). The surgeon mixes the powder and liquid components to initiate
the polymerization of the cement and when the powder-liquid mixture reaches a dough-like
consistency, the surgeon applies the cement at the surgical site for implant fixation. Even
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though the mechanical and physical properties of acrylic cements are widely studied and
well understood in literature, there are a number of drawbacks associated with these cements
such as high exothermic temperature, chemical necrosis due to residual monomer, stiffness
mismatch between cement and bone, aseptic loosening due to lack of integration with
surrounding bone, and lack of bioactivity, as discussed previously (25, 27). Therefore, there
is a vast interest in the development of new cement formulations to overcome a number of
drawbacks associated with the application of this material in vivo. The standard two-solution
bone cement (STSBC) developed in our laboratory has emerged as an experimental
alternative to the commercial powder-liquid formulations (28, 29) where the powder and
liquid components are pre-mixed in a two compartment polypropylene cartridge with one
side containing the initiator and the other side containing the activator. Thus, when the two
sides of the cartridges are mixed using a static mixing nozzle, the cement extruded is already
in the dough stage exhibiting a combination of clinical advantages that include ease of
mixing and delivery, reduced porosity, and better control of setting characteristics that can
be optimized by variations in the initiation chemistry of the cement (28). Nevertheless, a
few pitfalls associated with the STSBC, such as high initial viscosity and lower polymer
concentration calls for a further investigation of approaches to improve and optimize the
material for extended applications such as vertebroplasty (VP) and kyphoplasty (KP).
Therefore, the STSBCs have been modified with cross-linked PMMA nanospheres (ηTSBC) to reduce viscosity, increase polymer concentration and lower the exotherm
temperature (30, 31). However, these cements still lack the capacity to integrate with the
adjacent bone tissue. To that effect, the first goal of this study was to develop η-TSBCs with
improved bioactivity for injection into fractured vertebral bodies. Strontium-substituted
5

hydroxyapatite (SrHA) microspheres were fabricated and added to the cement mixture in
order to achieve a balance between the need of ideal viscosity, adequate mechanical and
radiographic properties, while simultaneously increasing bioactivity and antibiotic
properties. The second aim of this study was to evaluate the effect of the inclusion of the
bioactive filler material on the mechanical properties of the cement. Finally, the third goal
was to investigate whether addition of SrHA microspheres allowed for improvement in the
antibiotic properties of η-TSBC, since strontium is known to impart antibiotic properties
(32). The original idea of this work was conceived as a way of achieving improved
bioactivity, radiopacity, and antibiotic properties with addition of only a single filler
material with the ultimate goal of optimizing the physical and mechanical properties of this
formulation for applications such as cemented arthroplasties as well as VP and KP. The
bioactive properties are expected to improve the integration of the cement with the
surrounding bone tissue via formation of chemical bonds with the hydroxyapatite (HA)
present naturally in the bone.
The dissertation is organized along the following lines. It begins with an overall
background of the current technologies in the field of bone cements, followed by goals and
hypotheses of the work, then followed by three separate chapters written in manuscript form
describing major topics studied. The final sections are devoted to summarize the work and
also present a discussion of areas of future research that could be aimed at improving some
of the pitfalls of the present study.
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Chapter 2
______________________________________________________________________________

2

Background and significance
Compressive vertebral fractures caused by trauma are very common in patients with
osteoporosis. Percutaneous VP and KP are new techniques developed to stabilize vertebral
bodies post compression fractures caused by osteoporosis and other lesions (33, 34).
Because both these procedures involve percutaneous injection of bone cement into the
fractured vertebrae under real-time fluoroscopy, the most desirable properties of bone
cements for use in VP and KP are very high radiopacity, easy injectibility, low setting
temperature, bioactivity to allow for osseointegration thus enhancing bone strength, and
mechanical properties resembling those of non-osteoporotic vertebrae (5, 7, 27). Since most
commercial formulations of bone cement do not meet the viscosity criteria for use in the
spine, surgeons usually alter the polymer-to-monomer ratio recommended by manufacturers
by diluting the cement with higher monomer concentrations in order to decrease viscosity
and increase the handling and injection times (35). Radiopaque substances like barium
sulfate (BaSO4) and zirconium dioxide (ZrO2) have been added to bone cements in
concentrations ranging from 5 to 30 wt % in order to facilitate visualization under
fluoroscopy (36). Some studies have reported deleterious effects of BaSO4 in the
mechanical performance of the bone cements due to clumping and poor adhesion with the
cement matrix (36), as well as an increase in the in vivo cytotoxicity caused by BaSO4
particles released during wear (35).
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Two-solution bone cement is a viable alternative to current powder-liquid formulations,
having several advantages in comparison to commercial cements (28, 29, 37). A major
limitation to the use of STSBC in applications requiring injection through small needles or
cannulas is the higher initial viscosity of the material (28). Since the concentration of
monomer is already higher in STSBC (polymer-to-monomer (P:M) ratio 0.9:1) compared to
powder-liquid cements, a further reduction in the P:M ratio to make this material more
suitable for VP/KP applications could lead to even higher exothermal temperatures and
concentrations of residual monomer, which might have a direct impact on the mechanical
properties of the material and increase in vivo cytotoxicity. Nevertheless, STSBC can find
suitable application in VP/KP given its viscosity can be tuned by incorporation of crosslinked PMMA microspheres and nanospheres in the polymer phase (31).

2.1

Two-solution bone cements containing PMMA nanospheres (η-TSBC)
It has been observed that the viscosity of STSBC can be manipulated by subtle
changes in the P:M ratio and by addition of cross-linked PMMA microspheres (20 -100 μm
in diameter) and nanospheres (300-330 nm in diameter) in the polymer phase (30, 31). The
STSBC contains dissolved linear PMMA chains as compared to the modified η-TSBC, in
which a cross-linked dispersed particle phase is added to the linear PMMA, and this crosslinked phase does not dissolve but undergoes swelling in the monomer, thereby controlling
the cement viscosity (31). η-TSBCs exhibit a high degree of pseudoplasticity, which is
expected to facilitate injection of cements in VP/KP applications reducing the risk of
cement extravasation by viscosity recovery at the delivery site (31). Additionally, it is
observed that inclusion of the PMMA nanospheres in the cement lowers polymerization
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temperatures and increases setting times (12-20 mins) in comparison to the STSBC (~ 7
mins) while maintaining the flexural strength (30, 31). With the inclusion of the crosslinked phase a higher P:M ratio is also successfully achieved in comparison to STSBC.
Furthermore, the mechanical properties of η-TSBCs are comparable or superior to the
properties measured for the STSBC and it is feasible to prepare these cement formulations
at higher radiopacifier concentration up to 20% wt/vol of ZrO2 without affecting the
mechanical properties significantly (30). η-TSBCs exhibit several advantages over the
STSBC formulation for VP/KP applications, however, it still lacks in its ability to integrate
with the adjacent bone tissue to form a stronger bone and cement interface, and also in its
bactericidal characteristics. The η-TSBCs lack bioactivity and the ability to form apatite on
its surface.

2.2

Modification of η-TSBC to improve bioactivity
A solution to the above mentioned problem is to develop bioactive cement
particularly designed to produce a better interface between the cement and bone. Also, a
bioactive filler that is able to provide adequate radiopacity, bioactivity, and bactericidal
properties all at once, should be considered for incorporation into the η-TSBC. According
to a review by Harper et al. (38), there are two ways to go about development of
bioactive cements; firstly to improve the existing PMMA cement by addition of different
bioactive filler particles, e.g. HA added to PMMA cement (39), and secondly, develop an
all-bioactive cement, e.g. calcium phosphate cements (CPC) . CPC is self-setting, capable
of degradation, biocompatible, and has good bone conductivity, all of which are
properties that make it advantageous over PMMA (11). Bone Source, an injectable CPC
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cement developed by Stryker Orthopedics, was designed primarily to repair cranial
defects. Turner et al. (40) tested both PMMA and Bone Source cement in a canine
vertebral body defect and observed that both materials were well integrated
histologically. They also observed that CPC underwent resorption and remodeling and
demonstrated excellent biocompatibility and osteoconductivity in comparison to PMMA
cement. However, a major drawback with CPC is its rapid resorption rate which does not
provide enough time for the bone tissue to grow into the vertebral body defect (5). While
treating an osteoporotic vertebral fracture by cement augmentation, if the cement
resorption is faster than the new bone formation then it will have a contrary effect, as the
induced resorption will weaken the vertebral body further promoting its collapse (8).
Calcium sulfate cements, mainly known as plaster of Paris, have been used as a
bone graft substitute in various sites (7) due to its injectibility and osteoconductivity.
Turner et al. (41) have studied calcium sulfate bone graft substitute in a canine medullary
defect model and reported progressive resorption of the bolus of calcium sulfate within
the defect over a period of 13 weeks. Their histological evaluation at 13 weeks
demonstrated prominent osteoblastic rimming of the newly woven bone for all of the
medullary defects treated with calcium sulfate. However, these cements also have
drawbacks such as rapid resorption rates, low viscosity and difficult handling
characteristics (7). Due to its rapid resorption (42, 43), these cements are not expected to
support spinal alignment while it is undergoing remodeling, hence they would not be
appropriate for use in vertebral augmentation procedures. Another drawback associated
with these CPC and calcium sulfate cements is that they exhibit thixotropic properties
due to which when pressurized in a confined space such as a delivery tube, they dewater

10

from the suspension leaving a chalk that cannot advance through the delivery tube or
percolate through the bone interstices (8). The all-bioactive cements also are known to
have poor mechanical properties due to their faster resorption rates (5).
Since most commercial cements in current use are PMMA based, PMMA has
been largely investigated as the matrix material for bioactive cements. A variety of filler
particles have been incorporated into PMMA cements to improve bioactivity. Bone
particles (44) and growth hormones (45) have been used to impart bioactivity in PMMA,
however, glass ceramics (46) and HA (47, 48) are more promising and most studied
fillers. Shinzato et al. (49) developed PMMA cements with bioactive glass beads at
concentrations varying from 40 to 70 wt % and introduced the cements into the
intramedullary canals of rat tibiae to evaluate osteoconductivity over a period of 39
weeks. Their histological analysis revealed new bone formation along the cement
surfaces within 4 weeks, even at 40 wt% glass bead concentrations. Furthermore, in
another study Shinzato et al. (46) also compared addition of glass beads, apatite and
wollastonite containing glass ceramic (AW-GC) powder, and sintered HA powder into
PMMA cements at concentrations of each filler amounting to 70 wt%. The cements were
applied to the intramedullar canals of rat tibiae and osteoconductivity was determined at
2, 4, and 8 weeks post operation. At each time interval studied, Shinzato et al. (46)
reported a higher osteoconductivity for the glass bead cements in comparison to AW-GC
and HA cements. PMMA and alpha tricalciumphosphate (α-TCP) bioactive composite
cement was investigated in vitro and in vivo by Fini et al. (50), using MG-63 human
osteoblast cultures and PMMA+α-TCP implants in rabbit femoral trabacular bone,
respectively. They observed new bone formation inside the PMMA+α-TCP porosity
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indicating that the implants osseointegrated successfully in the trabecular tissue in vivo,
while a positive effect on osteoblast cultures was demonstrated in vitro by increased
levels of osteocalcin and pro-collagen. However, the differences in the newly formed
bone and the pre-existing normal tissue confirmed that the bone mineralization around
the bioactive composite material was a slow process.
Kobayashi et al. (51) studied the effect of introduction of three bioactive fillers
namely, apatite-wollastonite (AWC), tricalcium phosphate (TCP) and HA, on the cement
mechanical and biological properties. They concluded that AWC had superior biological
and mechanical properties in comparison to the other two fillers due to early and uniform
apatite formation on the cement surface (51). HA has been used widely as a bioactive
filler as it is the inorganic component of the bone tissue in vivo (39, 52, 53). However,
pure HA containing cements have been known to exhibit poor mechanical characteristics
(54). Sogal and Hulbert (55) and Dove and Hulbert (56) investigated mechanical
properties of HA reinforced PMMA cements. They studied the influence of HA powder
with varying particle sizes on the static and dynamic mechanical properties. The static
tests revealed that with an average particle size of 96 μm HA particles could only be
added up to 10% wt concentration without decreasing the tensile strength. A higher
concentration of 20 % wt HA resulted in a decrease in strength with all sizes of HA.
Besides imparting bioactivity characteristics to the cements, HA filler has two main
drawbacks: i) in most cases, the amount of filler that can be incorporated without
deleterious effects on the mechanical or handling properties is so small that the
improvement in bioactivity is not likely to be very large; (ii) the glass or ceramic fillers
tend to make PMMA even more brittle (38).
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Atomic substitutions have also been made in HA structure using magnesium,
zinc, strontium, or silver cations in order to improve the biological response of HA (57).
However, strontium substitution has been the most effective in promoting osteoblast
differentiation along with blocking osteoclastic bone resorption (58). Strontium uptake
and retention in the skeleton is also similar to calcium, and it can be cleared by urinary
and fecal excretions (58). Strontium ranelate is being developed as an antiresorptive drug
for treating osteoporosis since strontium promotes osteoblast differentiation and is easily
incorporated into bone via surface exchange or ionic substitution with calcium (59, 60).
Li et al. (54) developed bispheno-A-glycidyl methacrylate (Bis-GMA) bioactive cements
exploring a different matrix material in comparison to PMMA. They incorporated
strontium-substituted hydroxyapatite (SrHA) nano powder into Bis-GMA matrix, and
concluded that combination of strontium-HA was more beneficial than pure HA, as it
served as a radiopacifier and provided improved mechanical and bioactive properties.
However, the Bis-GMA dental resins were reported to have an uncured surface due to
inhibition of polymerization reaction by oxygen resulting in the incompletely
polymerized oligomers to leach from the cement surface (61, 62). Lin et al. (1) observed
an increase in antibacterial properties with increase in strontium substitution in HA nano
particles compared to pure HA nano particles. They carried out static (inhibition zone
test) and dynamic (shake flask method) antibacterial tests for HA, SrHA (totally
substituted) and SrCaHA (partially substituted) nanoparticles against Escherichia coli,
Staphylococcus aureus, and Lactobacillus strains. They observed that SrHA particles
exhibited antibacterial ability while statically or dynamically contacting the test bacteria,
whereas HA and SrCaHA nanoparticles had antibacterial ability only when they
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dynamically contacted the test bacteria. However they observed both SrHA and SrCaHA
nanoparticles to have higher antibacterial ratio than HA, and amongst them, SrCaHA had
the best antibacterial ratio indicating antibacterial properties improved after substitution
of calcium ions with strontium in HA nanoparticles. η-TSBCs formulated in our
laboratory for VP/KP applications also lack bioactivity and have PMMA as the primary
matrix material. Thus, in this study we explored the feasibility of modifying the η-TSBCs
by introducing SrHA microspheres to impart bioactivity, radiopacity and antibacterial
properties, all at once.

2.3

Applications of bioactive η-TSBCs
Compressive vertebral fractures caused by trauma are very common in patients
with osteoporosis. Although VP and KP offer potential benefits, the choice of filler
material will depend on the eventual development of the cement with good biomechanical
and biological properties along with good radiopacity and cost-effectiveness. η-TSBC has
been shown to be a suitable alternative for VP/KP applications due to its better
injectibility, radiopacity and mechanical properties (30, 31). With the introduction of
bioactive filler such as SrHA, η-TSBC is expected to improve in its biological response,
which would make it suitable for applications in cemented arthroplasties along with VP
and KP. This additional filler will not only impart bioactivity, but also impart radiopacity
and antibacterial properties to the PMMA matrix based cement. This would be expected to
be cost effective as no other additive or filler would be required in the polymer phase to
achieve all of the aforementioned properties. We also envision the use of this injectable,
antibiotic, and bioactive cement as an adhesive for acute treatment of fractures and injuries
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caused on the battlefields where an immediate stability and relief along with appropriate
infection control is required. The bioactive η-TSBC may also find suitable applications as
filler or scaffold materials in critical size defects in craniofacial and maxillofacial surgeries
(63, 64). Some studies have reported deleterious effects of bioactive fillers in the
mechanical performance of bone cements (5, 36, 53). Since it is desired to incorporate the
highest amount possible of SrHA microspheres to obtain higher bioactivity and bone
growth promotion, it is also important to predict the effect of increasing filler
concentration on the various properties of η-TSBCs. The following chapters provide a
detailed investigation of the bioactive and antibacterial properties of η-TSBCs containing
SrHA microspheres, along with evaluation of the effect of SrHA incorporation on their
static mechanical properties.
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Chapter 3
______________________________________________________________________________

3

3.1

Goals and hypotheses

First goal: Fabricate two-solution bone cements containing strontium-substituted
hydroxyapatite (SrHA) microspheres and characterize their bioactive properties
The first goal of this work focused on synthesis of SrHA microspheres for
addition into the η-TSBC formulation. A simple hydrothermal synthetic route was sought
for the production of SrCaHA/SrHA (partial and total strontium substitution of calcium)
microspheres. The bioactive performance (apatite forming ability) of the SrHA containing
cements was evaluated in vitro in a simulated body fluid (SBF) over a period of one
month. The effect of increasing microsphere concentration and the type of SrHA
microspheres (degree of strontium substitution in HA) on bioactivity was investigated and
compared to η-TSBC formulation without any filler.

Hypotheses:


The addition of SrHA/SrCaHA microspheres in the η-TSBC formulation will allow
for preparation of cements with improved bioactivity via increased apatite forming
ability on the cement surface when soaked in SBF, in comparison to the control ηTSBCs.



It is also hypothesized that with higher concentration of SrHA/SrCaHA in the
cement and lower percentage of strontium substitution in the microspheres there
will be an increase in apatite formation.
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Expected outcome: Increased apatite formation due to faster dissolution and
release of calcium ions from the SrHA/SrCaHA microspheres exposed at the
cement surface that would then help in forming apatite nuclei which can grow
spontaneously by consuming calcium and phosphate ions from the surrounding
simulated body fluid.

3.2

Second goal: Evaluate the effect of composition (degree of strontium substitution) and
concentration of SrHA microspheres on the flexural, compressive, and fracture
toughness properties of η-TSBCs
The second goal of this work focused on evaluating the effect of addition of
SrHA/SrCaHA microspheres on the static mechanical properties of η-TSBCs. The
concentration as well as the type of SrHA filler was varied. The compressive, flexural, and
fracture toughness properties were evaluated. These cements are expected to exhibit
adequate mechanical properties for use in VP/KP applications.

Hypotheses:


The incorporation of SrHA/SrCaHA microspheres at increasing concentration will
decrease the flexural and fracture toughness properties of η-TSBC



Expected outcome: An increase in the microsphere concentration may cause nonhomogeneous distribution and aggregation of these particles in the cement resulting
in poor adhesion to the cement matrix and weakening of the cement. Introduction of
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these microspheres is expected to increase brittleness in the η-TSBC formulation
due to weaker ductility of the bioactive filler.


The compressive properties of the SrHA/SrCaHA cements will increase with
increasing filler concentration due to increasing ceramic-like properties imparted by
SrHA/SrCaHA microspheres.



Expected outcome: Increase in the concentration of microspheres may increase
aggregation in the η-TSBC formulation creating internal flaws from which cracks
can propagate in tension, but not in compression as these particles can behave as
load carriers.



The type of microspheres, SrHA/SrCaHA, is not expected to have a significant
effect on the mechanical properties as they are structurally (morphology and size)
similar and differ only in the amount of strontium substitution.

3.3

Third goal: Investigate the antibiotic properties of the η-TSBC containing bioactive
strontium-substituted hydroxyapatite microspheres and determine the mechanism
behind bacterial inhibition
The third goal of this work focused on testing the antibiotic properties of η-TSBC
with incorporation of SrHA/SrCaHA microspheres at different concentrations. The shortterm and long-term antibiotic properties were evaluated in vitro by culturing E.coli biofilm
on cement surfaces for 24 hours and 14 days, respectively. The two proposed mechanisms
for bacterial inhibition were: 1) contact inhibition, direct contact of bacteria with the
SrHA/SrCaHA microspheres present on the cement surfaces, or by 2) surface dissolution
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of strontium ions from the SrHA/SrCaHA microspheres. In order to determine the
mechanism of biofilm growth inhibition, agar gel inhibition zone assays were performed.

Hypotheses:


The capacity to inhibit bacterial growth would increase with increasing
concentration and percentage of strontium substitution in SrHA/SrCaHA
microspheres added to η-TSBCs, as increase in the amount of strontium which is a
natural antibiotic, would result in improved antibiotic properties.



Expected outcome: The primary mechanism for bacterial inhibition is expected to
be via contact inhibition, as the SrHA/SrCaHA microspheres are expected to be
embedded firmly into the cement matrix not allowing for dissolution of enough
strontium ions into the surrounding fluid to cause bacterial inhibition. The cement
surface however, could be expected to have some exposed SrHA/SrCaHA particles
which could cause biofilm inhibition upon direct contact with bacteria.
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Chapter 4
______________________________________________________________________________

4

Injectable, bioactive two-solution bone cements with strontium-substituted
hydroxyapatite (SrHA) microspheres

Injectable, radiopaque two-solution bone cements (η-TSBC) have been
formulated with improved bioactivity. The bioactive components were partially (50%) and
totally (100%) substituted strontium-hydroxyapatite microspheres (SrCaHA and SrHA,
respectively), which were introduced in the cements at concentrations of 10%, 20%, and
30% wt/vol. The in vitro bioactivity of the cements was tested by introducing cement
samples directly in a simulated body fluid (SBF) solution maintained at 37°C (pH of 7.4) for
30 days to mimic in vivo conditions. Precipitation of an apatite-like layer was observed for
all the cement formulations containing SrHA and SrCaHA microspheres. The deposited
apatite layer was characterized for morphology using scanning electron microscopy (SEM),
and for composition, using Fourier transform infra-red spectroscopy (FTIR) and energy
dispersive x-ray (EDX) analysis. Radiopacity of the cements was observed to increase
linearly with increasing SrHA/SrCaHA filler concentration. A significant increase was
observed in the atomic percentages of calcium, oxygen, and phosphorus on all of the
SrHA/SrCaHA cement surfaces after 30 days in SBF indicating the presence of apatite.
However, no significant differences were observed in the bioactivity between all
formulations of SrHA and SrCaHA cements. This study showed that the apatite formation
ability of SrHA and SrCaHA cements was effective in improving the bioactivity of current
polymethylmethacrylate (PMMA) containing η-TSBCs.
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4.1

Introduction
Polymethylmethacrylate (PMMA) was and still is the gold standard for fixation of
total hip prosthesis, percutaneous vertebroplasty (VP), and kyphoplasty (KP) (5, 7, 37, 38,
57). However, PMMA is bioinert, biologically non-degradable, and hydrophobic, which
hinders the formation of biological apatite, a major inorganic component of natural bone,
on the surface of this polymer (5, 8, 11, 65, 66). Due to this lack in bioactivity of acrylic
cements, bioactive bone cements have been developed to overcome the problems of
conventional PMMA (38, 39, 51, 52, 67-69). Unlike PMMA cements, the bioactive
cements can integrate with the living tissue via the apatite layer formed on the cement
surface owing to rapid formation of chemical bonds with the hydroxyl groups of HA in the
surrounding bone tissue. In an attempt to balance the mechanical and biological
characteristics, since PMMA naturally does not allow formation of apatite on its surface, a
variety of bioactive fillers based on calcium phosphates, hydroxyapatite powders or
bioactive glass-ceramics have been used in combination with PMMA to form acrylicceramic formulations (4, 11, 51, 52, 65, 69-72).
Calcium phosphates are known to have excellent biocompatibility and
osteoconductivity; however, they have weaker mechanical strengths compared to PMMA
cements, to be considered for the use of load bearing applications (8, 57). Recently, a
number of alternatives to the basic MMA/PMMA system have been explored including
bioactive filler and bisphenol A diglycidylether dimethacrylate (Bis-GMA) systems that
have improved bioactivity (53, 66, 73). Comparing cements based on Bis-GMA and
PMMA, it has been reported that for the PMMA cements the bioactive filler remained
embedded in the cement matrix leading to failure of formation of apatite layer. However,
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Bis-GMA cements tend to have uncured surfaces due to inhibition of polymerization
reaction by oxygen resulting in the incompletely polymerized oligomers to leach from the
cement surface that has a cytotoxic effect (61, 62). Also, a more recent study by Hernandez
et al. (74) has demonstrated in vitro and in vivo bioactivity of PMMA cements charged
with bioactive components such as SrHA nano powder (10% Sr substitution). They explain
that when the cement is implanted at the dough stage in the body or directly in simulated
body fluid (SBF), the PMMA cement is not completely polymerized and a partial
dissolution of the cement surface can leave the bioactive particles exposed to the medium,
leading to their bioactive response. It is thus clear that PMMA based cements can offer
alternative bioactive solutions to VP and KP techniques.
Lately Li et al. (66) and Ni et al. (75) have reported Bis-GMA cement
formulations composed of strontium-containing hydroxyapatite (SrHA) nanopowder that
demonstrated good radiopacity and suitable in vivo bioactivity. Hydroxyapatite (HA), as a
natural component of bone mineral, has been used as a graft material for bone repair,
augmentation, and substitution for decades (8, 38). However, its biological performance
itself requires improvement as it has limited intrinsic osteoconductive properties (76) and
as mentioned earlier they provide weaker mechanical strengths in load bearing
applications. Many studies (76-78) however, have looked into ionic-substitutions of HA
with strontium (SrHA) which results in the distortion of its structure and a significant
increase in the solubility of HA with a constant release of strontium and calcium ions
leading to eventual precipitation of apatite in the surrounding fluid, thus improving the
biological response of HA. Strontium is also a trace element found in human body having
the ability to not only increase osteoblast-related gene expression and alkaline phosphatase
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(ALP) activity of mesenchymal stem cells, but also inhibit osteoclast differentiation (2, 58,
59, 79, 80). Strontium has chemical similarity to calcium, thus it allows for radiographic
visualization without the need for additional radio contrast material and can be readily
substituted for calcium in bone in vivo (59). Strontium is also known to impart
antibacterial properties (1, 4). SrHA has also been reported to have stronger mechanical
properties and better bioactivity than pure HA (66, 76). In vivo studies by Ni et al. (73, 75)
and Cheung et al. (70) on cements containing SrHA nanopowder (10% Sr) showed that
SrHA cement could bond directly to the adjacent bony tissue which facilitated new bone
formation along the cement surface indicating good bioactivity and osteoconductivity.
Our group has developed modified two-solution bone cements containing crosslinked PMMA nanospheres (η-TSBC) for applications of VP and KP (81, 82). In this study,
we have developed bioactive bone cement by incorporating SrHA with the aim of
improving the bioactivity of η-TSBC for VP and KP applications. We have synthesized
SrCaHA and SrHA microspheres by hydrothermal synthesis with the Sr substitution
degree, respectively, at 50% and 100%. In this chapter, we report the study of the in vitro
bioactivity of η-TSBCs containing SrHA/SrCaHA microspheres in the presence of
simulated body fluid (SBF) and test their ability to form apatite on their surfaces.

4.2

Materials and Methods

4.2.1 Preparation and characterization of SrHA/SrCaHA microspheres
The SrHA and SrCaHA microspheres (2-5 μm in diameter) were synthesized as
described by Zhang et al. (2, 83) and the atomic ratios of Sr/P and (Ca+Sr)/P were set as
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1.67. To this end, a solution of 3 mmol of strontium nitrate [Sr(NO3)2] and 0.3 g of
surfactant hexadecyl-trimethylammonium bromide (CTAB) in 40 ml of deionized water
was prepared along with a second solution composed of 6 mmol trisodium citrate (Cit3-)
and 2 mmol of ammonium dihydrogen phosphate [NH4H2HPO4] in 25 ml of deionized
water. After vigorously stirring the individual solutions for 30 minutes the two solutions
were mixed and allowed to stir for another 20 minutes. The as-obtained mixing solution
was then transferred to a Teflon bottle held in stainless steel pressure vessel (Parr
Instruments), sealed and maintained at 180°C for 24 hours. The SrCaHA microspheres
were prepared using the same hydrothermal procedure, however in this case the first
solution contained a total of 3 mmol of calcium nitrate [Ca(NO3)2] and [Sr(NO3)2] with a
[Sr/(Sr + Ca)] molar ratio of 0.5 in the reaction mixture. The chemical compositions of
the powders were investigated using Fourier transform infrared microscopy (FTIR). The
morphology and elemental composition of the samples were inspected using a scanning
electron microscopy (SEM) equipped with an energy dispersive X-ray system (EDX,
JEOL 5600). The atomic percentages of C, O, P, Sr, and Ca were obtained using the
exCalibur software of the EDX set up. The software performs a semi-quantitative
analysis by applying a ZAF correction (atomic number, absorptivity and fluorescence
correction) after detection and calculation of net intensities of x-rays from the x-ray
detector. Net intensities are collected and a Gaussian peak deconvolution is performed to
get initial estimates of the concentrations of each element. In order to compute the net
intensities, the software calculates the net region of interest (ROI) integrals and then
applies the ZAF corrections in order to correct the intensities for overlaps and peaks
fractions.
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4.2.2 Bone cement preparation
The two-solution bone cements containing cross-linked polymethylmethacrylate
nanospheres (η-TSBC), used as controls, were prepared as described by Rodrigues and
co-workers (81, 82) at a polymer to monomer ratio of 1:1 and cross-linked PMMA
nanospheres to linear PMMA ratio of 1.5:1. For the preparation of η-TSBCs, benzoyl
peroxide (BPO) (Aldrich), N, N-dimethyl p-toluidine (DMPT) (Aldrich) and
methylmethacrylate (MMA) (Fluka) were used as received without further purification.
η-TSBCs had two polymer phases: 1) dissolved linear PMMA (Pl), and 2) dispersed
cross-linked PMMA nanospheres (Pb). These two components were massed and mixed
together forming the powder phase (P). The total volume of MMA was split and added to
two graduated cylinders, in which one was mixed with 1.25 g of BPO (1.25 g/100 ml of
MMA) and other with 0.7 ml DMPT (0.7 ml/100 ml of MMA). The two mixtures
BPO/MMA and DMPT/MMA were transferred to two polypropylene cartridges followed
by the addition of the powder phase and remaining MMA. The cartridges were sealed,
vigorously agitated by hand, and placed on a rotating drum mixer for 18 h. Following
mixing, the cartridges were stored upright at 4°C for 48 hours before use. In order to
prepare the η-TSBCs containing strontium substituted microspheres, the SrHA and
SrCaHA microspheres were added to the polymer phase at concentrations of 10, 20, and
30% wt/vol of MMA and the mixing procedure remained the same as described above for
the η-TSBCs. The cements were then injected into square molds (0.5 inch in length and
1mm in thickness) and allowed to polymerize to create samples for the bioactivity tests.

4.2.3 Optical density measurements
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Optical density measurements were obtained from digital X-ray images taken in
air at an X-ray tube voltage of 41 kV (82). Three cylindrical (6 mm in diameter and 12
mm height) cement specimens each of the fixed composition of η-TSBC containing 0
(controls), 5, 10, 20, and 30% wt/vol SrHA and SrCaHA microspheres were imaged
under the X-ray and their degree of contrast was compared with that of η-TSBC
containing 20% wt/vol zirconium dioxide (ZrO2). The radiopacity of SrHA/SrCaHA
cements were compared to the 20% ZrO2 composition, as this cement had contrast value
similar to the commercially available Kyphx cement containing 30% wt barium sulphate
(82). Radiopacity is determined by looking at the contrast of the X-ray images. Contrast
is determined using the following equation defined by Kjellson et al. (84)(83)(83);
Contrast = (Imax – Imin)/ Imax
where Imax represents transmittance through the background (brightness) and Imin the
transmittance of the subject. Image J was used to measure the gray scale of the specimens
and of the immediate background (82). The average contrast and standard deviations
were calculated for each group of samples. The differences in contrast with increasing
concentration of SrHA/SrCaHA microspheres were statistically evaluated using two-way
ANOVA with a Tukey post-hoc test at a level of significance of 95%.

4.2.4 In vitro bioactivity
The in vitro test was performed in a simulated body fluid (SBF) medium. From
various studies in literature it has been concluded that examination of apatite formation
on a material in SBF can be useful for predicting the in vivo bone bioactivity of a material
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(74, 85, 86). The SBF medium was prepared at pH 7.4 as per Kokubo et al. (85) with ion
concentrations nearly equal to human blood plasma (Appendix C). Three square cement
samples of 0 (controls), 10, 20, and 30% SrHA and SrCaHA compositions were
evaluated for in vitro bioactivity by immersion in SBF at 37°C for a period of 30 days.
All of the cement surfaces were examined before immersion in SBF by SEM equipped
with an EDX system (JEOL 5600). After 30 days of immersion, the samples were
extracted from the solution, rinsed with deionized water and allowed to dry in a
dessicator. The desiccated cement surfaces were once again examined under SEM and
EDX with an accelerating voltage of 15 kV to test whether deposition of apatite had
occurred. The study of the composition of the deposited apatite layer on the SrCaHA
cement surfaces was carried out by FTIR spectroscopy. A line scan spectra with EDX on
the 20% SrHA cement surface was also obtained along the areas devoid in apatite going
across areas containing the apatite layer, and the changes in the intensity of 5 elements
namely, carbon (C), phosphorus (P), oxygen (O), calcium (Ca), and strontium (Sr), were
recorded. The cross-section of 10% SrHA and SrCaHA cement samples after immersion
in SBF for 30 days were also evaluated using SEM and EDX to test for the presence of
apatite formation in the bulk of the cement. The apatite layer thickness was measured
from the SEM micrographs of all cement surfaces using ImageJ software by NIH. The
changes in the pH of SBF medium were measured at pre-determined time intervals (0, 1,
2, 3, and 4 weeks) using a pH meter. The differences in the apatite thickness and atomic
percentage for C, O, P, Ca, and Sr before and after submersion in SBF with increasing
concentration of SrHA/SrCaHA microspheres were statistically evaluated using two-way
ANOVA with a Tukey post-hoc test at a level of significance of 95%.
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4.3

Results

4.3.1 Characterization of SrHA/SrCaHA microspheres
The SrHA and SrCaHA microspheres were synthesized directly by hydrothermal
treatment at 180 °C for 24 hours. Figure 1 (a, b) shows SEM micrographs of typical
SrHA and SrCaHA samples. It can be seen that the microspheres are about 2-5 μm in
diameter and are not random aggregates but are ordered self-assembly of nanosheets.
Figure 1 indicates that the nanosheets are assembled in a radial form from the center to
the surface of the microsphere, as also observed by Zhang and co-workers (77) using
transmission electron microscopy. In Figure 1(c), the FTIR result indicates the presence
of characteristic peaks representing the phosphate (PO43-) and carbonate (CO32-) groups.
The bands centered at 1080 and 1018 cm-1 wave numbers were ascribed to the
asymmetric stretching vibrations of the P-O, and the band at 949 cm-1 was assigned to the
symmetric stretching mode of the P-O in PO43- groups. In addition, two groups of bands
observed in the low wave number region from 490 to 630 cm-1 (center: 560, 595 cm-1)
were due to the bending vibrations of the O-P-O in PO43- groups. The range of 1300-1600
cm-1 clearly showed the existence of the carbon-related impurities from the organic
additives employed during the synthesis.
The EDX spectrum (Figure 1(d)) of the SrHA product shows the presence of
strontium (Sr), phosphorus (P), oxygen (O), and carbon (C) peaks, while that of SrCaHA
sample shows the presence of the additional calcium (Ca) peaks between binding
energies 3-4 keV. Table 1 lists the element content analysis results of Ca, Sr, and P. As
compared with the pre-set atomic ratios, the measured atomic % ratios of Sr/P,
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(Ca+Sr)/P, and Sr/(Sr+Ca) were maintained roughly as intended values, indicating the
reaction was performed according to the predetermined stoichiometric ratios.

1 (a)

(b)

(c)

(d)

Figure 1. SEM micrographs of as prepared, self-assembled (a) SrHA and (b) SrCaHA microspheres (2-5
μm in diameter). (c) FTIR spectra of SrHA and SrCaHA powders indicating the presence of the phosphate
(PO43-) peaks. Asterisk represents the significant phosphate peaks. (d) EDX spectra of SrHA and SrCaHA
powders. The spectrum for SrCaHA powder shows the additional calcium peaks indicating half-substitution
of calcium ions with strontium ions.

Table 1. The elemental content analysis results of Ca, Sr, and P from the EDX spectrum of SrHA and
SrCaHA samples. Calculated Sr/P, (Ca+Sr)/P, and Sr/(Sr+Ca) ratios of the prepared strontium-substituted
hydroxyapatites by EDX (see Figure 2(b) (mean ± SD, n = 3)
Sample
SrHA
SrCaHA

Ca (at %)
0
15.76 ± 0.52

Sr (at %)
40.43 ± 1.83
18.35 ± 3.3

P (at %)
24.21 ± 1.08
20.45 ± 1.7

Measured atomic % ratio
Sr/P
1.66 ± 0.005
(Ca+Sr)/P
1.67 ± 0.019
Sr/(Sr+Ca)
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0.51 ± 0.004

4.3.2 Optical Density
Radiographs of the various cement formulations were obtained as illustrated in
Figure 2(a-j), and the optical densities of all compositions are compared in Figure 2(k).
Specimens containing no filler (0%, Controls) were not completely transparent to X-rays.
There was a significant linear increase in the contrast values with increasing
concentration of SrHA (r2 = 0.94) and SrCaHA (r2 = 0.98) microspheres (p < 0.05).
However, no significant differences were observed in the contrast values between the
SrHA and SrCaHA cement compositions at each concentration. The 20% and 30% SrHA
composition were significantly different than the controls (0%) and 5% SrHA cements (p
< 0.05), while the 5% and the 10% SrHA compositions were not significantly different.
Similar results were observed for the SrCaHA cement compositions. The 30% SrHA and
the 30% SrCaHA compositions were observed to have higher contrast values that were
comparable to the contrast value observed for 20% ZrO2 η-TSBC. However, the 20%
SrHA and SrCaHA cements also provided radiographic contrast values of 0.55 ± 0.05
and 0.50 ± 0.08, respectively.
These results fall in between the contrast values reported by Kjellson et al. (84)
for acrylic bone cement specimens containing 5% (contrast value 0.339) and 15%
(contrast value 0.73) ZrO2 imaged under similar X-ray tube voltage (40 kV) and
conditions applied in this study. Also, cements containing ZrO2 and strontium were
expected to have opacities higher than those cements containing barium sulfate when
imaged at an accelerating voltage of 40 kV because this voltage produces its peak
intensity at a photon energy of 20kV which is just above the zirconium (~18 kV) and
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strontium (~16 kV) k border (84). The cements containing ZrO2 and strontium filler were
expected to have similar opacities.

2 (a)

(b)

Controls (0% filler)
(f)

(c)

5 % SrHA

(g)

20 % ZrO2

10 % SrHA

20 % SrHA

10 % SrCaHA

30 % SrHA
(j)

(i)

(h)

5 % SrCaHA

(e)

(d)

20 % SrCaHA

30 % SrCaHA

2 (k)

Figure 2. Radiographic images of η-TSBC prepared at (a) 0% (controls), (b) 5% SrHA, (c) 10% SrHA, (d)
20% SrHA, (e) 30% SrHA, (f) 20% ZrO2, (g) 5% SrCaHA, (h) 10% SrCaHA, (i) 20% SrCaHA, and (j)
30% SrCaHA. Cements prepared at 0% SrHA/SrCaHA were not completely transparent to X-rays. (k)
Comparison of the radiographic contrast values of η-TSBC preparations with increasing concentration of
SrHA/SrCaHA microspheres. The data showed a significant linear increase in radiopacity with increasing
SrHA/SrCaHA microsphere concentration.

4.3.3 Bioactivity
The bioactivity of cements was evaluated in vitro after 30 days of immersion in
SBF. All of the SrCaHA and SrHA cement surfaces presented deposition of small
31

particles which were identified as apatite by SEM and EDX analysis. The SEM
micrographs and EDX spectra of the resulting SrCaHA and SrHA surfaces are shown in
Figure 3(a-d) and 4(a-d), respectively, together with that of their initial surfaces. For the
control cements containing no microspheres, no deposition of apatite was found as
observed from the SEM micrograph and EDX analysis before and after immersion in
SBF (Figure 3(a), 4(a)). The surface composition of the SrCaHA and SrHA cements
before and after soaking was analyzed by EDX and the recorded spectra are shown in
Figures 3(a-d) and 4(a-d). The intensity of the signals corresponding to calcium,
phosphorus, and oxygen atoms increased on the SBF soaked surfaces of the SrHA and
SrCaHA samples of all concentrations, and a decrease in the signal assigned to carbon
was also observed that could be explained by the deposition of apatite on their surfaces.
The composition of the deposited apatite layer on the SrCaHA cement surfaces
was also analyzed by FTIR and the FTIR spectra for 10, 20, and 30% SrCaHA samples
are shown in Figure 5. The FTIR spectra of all the SrCaHA samples soaked in SBF
showed a band at 1730 cm-1 corresponding to the stretching vibration of the carbonyl
groups of PMMA and the band at 1025 cm-1 corresponding to the vibration of the
phosphate groups of the hydroxyapatite, indicating that the surface became richer in
apatite. Figure 6(a, b) compares the EDX spectra and Figure 6(c, d) quantifies the atomic
percentages of C, P, O, Ca and Sr atoms before and after being soaked in SBF, for all
concentrations of SrHA and SrCaHA cements. There were significant increases (p <
0.05) observed in the atomic percentages of P, O, and Ca and a significant decrease in the
atomic percentage of C, on all samples except the controls, after being soaked in SBF for
30 days. However, no significant differences were observed in the atomic percentages of
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all the elements between the SrHA and SrCaHA compositions at all concentrations before
being soaked in SBF. Also, no significant differences were observed in the atomic
percentages of all the elements between the SrHA and SrCaHA compositions at all
concentrations after being soaked in SBF.

3 (a)

Before

4 wks in SBF

Controls

(b)

A

10% SrCaHA

(c)

A

C

20% SrCaHA

(d)

A
30% SrCaHA

C

Figure 3. SEM micrographs and EDX spectra of the SrCaHA cement surfaces before (left panel) and after

immersion in SBF at 37°C for 30 days (right panel). From top to bottom: (a) Control (0% wt/vol), (b) 10%
wt/vol SrCaHA, (c) 20% wt/vol SrCaHA, and (d) 30% wt/vol SrCaHA. Apatite formation was observed on
all the SrCaHA containing cement surfaces after 30 days in SBF along with an increase in the atomic
percentage of calcium, phosphorus, and oxygen. (A = apatite layer, C = PMMA cement)
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4 (a)

Before

4 wks in SBF

Controls

(b)

A
10% SrHA

(c)

A
20% SrHA

C
(d)
30% SrHA

A

C

Figure 4. SEM micrographs and EDX spectra of the SrHA cement surfaces before (left panel) and after
immersion in SBF at 37°C for 30 days (right panel). From top to bottom: (a) Control (0% wt/vol), (b) 10%
wt/vol SrHA, (c) 20% wt/vol SrHA, and (d) 30% wt/vol SrHA. Apatite formation was observed on all the
SrHA containing cement surfaces after 30 days in SBF along with an increase in the atomic percentage of
calcium, phosphorus, and oxygen. (A = apatite layer, C = PMMA cement)

5)

Figure 5. FTIR spectra of apatite layer formed on the surface of 10%, 20%, and 30% wt/vol SrCaHA
cements soaked in SBF at 37°C for 30 days. All of the spectra obtained showed the presence of phosphate
peaks (Asterisks) confirming the presence of apatite.
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6 (a)

6 (c)

6 (b)

6 (d)

Figure 6. (a) EDX spectra of 0, 10, 20 and 30% SrCaHA samples before and after immersion in SBF for 30
days. (b) EDX spectra of 0, 10, 20 and 30% SrHA samples before and after immersion in SBF for 30 days.
Changes in the atomic percentages of C, O, P, Ca, Sr on the 0, 10, 20 and 30% SrCaHA and SrHA sample
surfaces (c) before and (d) after immersion in SBF for 30 days. A significant increase in the atomic
percentages of O, P, and Ca for all the SrHA and SrCaHA cement compositions was observed after 30 days
in SBF. However, no significant changes were observed in the atomic percentages of all the 5 elements for
the control samples, before and after immersion in SBF.

The SEM micrograph of a 20% SrHA cement surface, shown in Figure 7(a),
revealed a distinct region of apatite layer (A) and a region of the cement without apatite
(C). A line-scan EDX (Figure 7(b)) performed along the line plotted (500 points) on the
SEM micrograph in Figure 7(a), showed a progressive increase in the intensity of O, P,
and Ca levels as one moves from the cement surface onto the apatite layer formed. The
increase in the Ca, O, and P intensities at the cement-apatite interface also validates the
formation and presence of apatite on the cement surface after being soaked in SBF. The
cross-sections of the 10% SrHA and SrCaHA cement samples, soaked in SBF for 30
days, were evaluated for presence of apatite in the bulk of the cement using SEM and
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EDX as shown in Figure 8. Figure 8 (a, b) shows the SEM micrograph of the crosssections of the 10% SrCaHA and 10% SrHA cement surfaces, respectively. The EDX
spectra of the cross-sectional areas, shown in Figure 8(c), showed no presence of any
calcium or phosphorus peaks corresponding to apatite. Also, the quantification of the
atomic percentages (Figure 8(d)) of the elements from the EDX spectra in Figure 8(c)
showed that only carbon and oxygen were present in both the cement cross-sections,
indicating no formation of apatite in the bulk of the cement.

7 (b)

7 (a) 20% SrHA

*
A

*

C

*

Cement

Apatite layer

Figure 7. (a) SEM micrograph of a 20% SrHA cement surface after being soaked in SBF at 37°C for 30
days, having regions devoid of apatite (C) and regions having apatite (A) formed on its surface. (b) EDX
line scan spectra, performed along the line plotted (500 points) on the SEM micrograph region in Figure
(a), showing a progressive increase in the intensity of O, P, and Ca levels as one moves from the cement
surface onto the apatite layer formed.
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8 (a)

10% SrCaHA

(c)

(d)
(b)

10% SrHA

Figure 8. SEM micrographs of cross-section of the (a) 10% SrCaHA and (b) 10% SrHA cement samples
soaked in SBF for 30 days. (c) EDX spectra across the cross-section of the 10% SrCaHA and 10% SrHA
cement surfaces and the (d) Atomic percentage of the elements analyzed by EDX spectra. The EDX spectra
of the cross-section surfaces of both the cement compositions clearly showed no presence of any apatite,
indicating that apatite was not formed in the bulk of the cement.

Figure 9(a-d) shows SEM micrographs depicting different thicknesses of the
apatite that were observed on various cement surfaces. The thickness of the apatite layer
formed on all of the SrHA and SrCaHA cement compositions was measured using
ImageJ and was plotted as a function of filler concentration as seen in Figure 9(e). The
thickness of apatite layer on SrCaHA cements was observed to decrease significantly
with increasing SrCaHA concentration (p < 0.05). However, no particular trend was
observed in the thickness of the apatite layer with increasing SrHA concentration. The
20% SrHA cement surface had significantly thicker apatite layer in comparison to 10 and
30% SrHA compositions. The changes in the pH of SBF were also measured at timed
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intervals over a period of 30 days. Figure 10 shows a graph of pH versus time which
illustrates a gradual significant increase (p < 0.05) in the pH of SBF containing 10 and
20% SrHA and SrCaHA cement samples, up until 4 weeks. However, no significant
changes were observed in the pH of SBF containing the control cement samples, and the
pH remained constant at 7.4 over a period of 4 weeks. The increasing alkalinity of SBF
containing SrHA and SrCaHA samples could possibly be explained by increase in
calcium ion concentration in the solution during apatite formation on the cement surfaces.

9 (a)

(b)

~ 10-12 μm thick

~ 18 -20 μm thick

(c)

(e)

~ 5-7 μm thick
(d)

~ 3-5 μm thick

Figure 9. SEM micrographs indicating the different thicknesses of the apatite layer formed on surfaces of
various cement compositions (a) 20 μm in thickness, (b) 10 μm in thickness, (c) 5 μm in thickness, (d) 3
μm in thickness. (e) Apatite layer thickness measured as a function of the filler concentration. A decrease
in apatite thickness was observed for the SrCaHA cements with increasing filler concentration, whereas no
particular trend in the apatite thickness was observed for the SrHA cements with increasing filler
concentration.
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Figure 10. The changes in the pH of SBF medium containing controls (0% filler), 10% SrHA, 20% SrHA,
10% SrCaHA, and 20% SrCaHA cement samples (n = 3), over a period of 4 weeks. The pH vs. time graph
illustrated that pH of the SBF containing control samples remained constant at 7.4, whereas the pH of SBF
containing SrHA and SrCaHA cement samples increased significantly over a period of 4 weeks as
compared to the control samples, indicating the relative alkaline effect on the pH of the medium due to
addition of apatite.

4.4

Discussion
The FTIR comparison of SrHA and SrCaHA powders is shown in Figure 1(c).
The decrease in the wave numbers of the P-O bonds is attributed to the substitution of
strontium ions (Sr2+) for calcium ions (Ca2+) into the lattice of apatite. The radius of Sr2+
(0.112 nm) is bigger than the radius of Ca2+ (0.100 nm), which consequently decreases the
bonding strength of the P-O bonds (1). These changes further confirm that Sr2+ can
substitute Ca2+ and enter the lattice of apatite. The detected carbon in the EDX spectra of
the microspheres (Figure 1(d)) (as also observed in the FTIR spectra (Figure 1(c))),
indicates that some carbon impurities have been induced into the SrHA/SrCaHA host
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lattices and/or the surface due to the organic additives employed during their hydrothermal
synthesis. Hernandez and co-workers developed PMMA cement containing SrHA nano
powder (10% Sr substitution) that had radiopacity similar to that provided by addition of
30% wt/vol barium sulfate radiopacifier which met the requirements of vertebroplasty
(68). The radiopacity of cements prepared at higher concentrations (20 and 30% wt/vol) of
SrHA/SrCaHA microspheres were observed to have similar contrast values as measured
for cements prepared with ZrO2 (82), suggesting they can provide sufficient radiographic
contrast for VP and KP applications. This observation is important considering that
SrHA/SrCaHA microspheres were added to two-solution cements instead of ZrO2 in order
to impart radiopacity and bioactive properties, without incorporation of any additional
filler material. As expected, the radiopacity increased linearly with increasing
concentration of SrHA and SrCaHA microspheres.
Bioactivity of a material in vivo is determined through its ability to deposit an
apatite layer on its surface, which in the long term facilitates formation of new bone
matrix providing direct contact between the implant and bone (87). This phenomenon can
be reproduced in vitro by immersing the material in SBF, a fluid with ion concentrations
similar to human blood plasma but free of proteins and cells. The most employed SBF is
that proposed by Kokubo et al. (85) and it has been used in the conditioning of the
samples in this work. In this study, all compositions of SrHA and SrCaHA cements
exhibited the ability to induce apatite formation on their surfaces after a month in SBF.
The presence of apatite layer and the capacity to form apatite on these surfaces was an
indication that these cements had improved bioactivity compared to the control η-TSBCs.
EDX analysis also revealed decreased levels of C and increased levels of Ca, P, and O on
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these cements after 30 days in SBF indicating presence of apatite. A similar increase in Sr,
Ca, and P signal and a decrease in signal assigned to C were also observed by Hernandez
et al. (74) after soaking PMMA cements containing SrHA nanopowder (10 mol % Sr
substitution) in SBF for 28 days. They suggested these elemental changes to be a result of
apatite deposition on their cement surfaces. They cured their cements in air as well as
directly in SBF and suggest the growth of apatite particles was mainly produced within the
superficial pores left by dissolved initial particles. However, Hernandez et al. (74)
incorporated SrHA nanopowder at concentrations of only 10 wt % and 20 wt % and
observed apatite formation only on cement surfaces containing 20 wt% SrHA nanopowder
that was pre-treated with MMA. We observed apatite formation even on our η-TSBC
cement surfaces containing lower concentrations (10% wt/vol) of SrHA/SrCaHA
microspheres, which is a promising result. The FTIR analysis also confirmed presence of
apatite. However, the type or concentration of microspheres did not significantly affect the
apatite formation ability of the SrHA/SrCaHA cements. The formation of the apatite layer
on a HA surface in vivo has already been described by Kokubo et al. (52). The most
commonly proposed mechanism for bioactivity involves dissolution of calcium and
phosphate ions with subsequent supersaturation of these ions near the implant vicinity
leading to their precipitation and formation of biological apatite (80, 88). However, an in
vivo study by Wong et al. (89) looking at the mineralization of SrHA nano powder/BisGMA bioactive cement injected into the cancellous bone of the ilium of rabbits, suggested
that dissolution of SrHA (10 mol% Sr substitution) into the debris by the bone remodeling
process increased the concentration of calcium and phosphorus at the bone-SrHA cement
interface. The crystalline SrHA thus formed an amorphous layer on the cement surface
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which then dissolved into the surrounding solution leading to oversaturation and
precipitation of apatite crystals. They proposed that the cells resorbed and modified the
surface of SrHA cement to promote osseointegration. Also, many studies (69, 76, 90)
indicate that introduction of Sr introduces more lattice distortions to the structure of HA
increasing its solubility and release of Ca which in turn increases the ionic activity of
apatite in the surrounding fluid, inducing apatite formation. In our study, we varied the
amount of Sr substitution in HA at 50 mol % and 100 mol % and thus the SrHA/SrCaHA
microspheres exposed at the cement surfaces are expected to have higher solubility when
subjected to SBF solution. Interestingly, we also observed a gradual increase in the
alkalinity of the pH of SrHA/SrCaHA containing η-TSBCs after 4 weeks in SBF
indicating an increase in concentration of Ca2+/ Sr2+ ions. This could be one of the possible
mechanisms of formation of apatite on our SrHA/SrCaHA η-TSBCs. The SrHA/SrCaHA
microspheres exposed at the cement surfaces could facilitate faster dissolution of Ca2+ ions
into the SBF. The nucleation and formation of apatite on SrHA cements could also be
explained due to super saturation of Sr ions in the fluid and interaction with Ca ions in the
surrounding SBF medium, since Sr can be easily exchanged by Ca. The SEM micrograph
of 30% SrHA sample after 4 weeks in SBF (Figure 4(d)) also showed evidence of
individual dome like formations of apatite on some areas of the cement surfaces indicating
that the microspheres provided sites of nucleation for apatite formation followed by
gradual growth and progression of these dome structures into layers of apatite. Such an
increase in pH has also been observed by Boanini et al. (91) who studied the effect of
SrHA (10 mol% Sr substitution) and HA nano powder on rat osteoblasts. They measured
the calcium and Sr cumulative releases from compacted discs of SrHA and HA powder in
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physiological solution over a period of 14 days, and found that the sum of Ca and Sr
released from SrHA was always greater than the extent of Ca release from pure HA. Fathi
et al. (86) also tested the bioactivity of HA nanopowder versus conventional HA in SBF
for a period of 14 days and measured the changes in pH of SBF at timed intervals. They
concluded that pH value was dependent on the solubility of HA and drastic changes were
seen in the pH of SBF containing HA nanopowder, suggesting it dissolves faster than
conventional HA.
The decrease in the apatite layer thickness with increasing concentration of
SrCaHA microspheres was not expected. The apatite layer formed on the SrCaHA
surfaces was attached loosely to the cement surface and flaked off easily upon drying and
preparing the cement for SEM analysis. While performing the SEM analysis it could be
possible that some of the apatite layer was detached and thus the thickness measurements
from these SEM images were not an accurate representation of the actual apatite thickness.
Future work would involve looking at better techniques to measure apatite thickness such
as a profilometer. The apatite thickness observed for SrHA samples in our study did not
follow a particular trend with increasing SrHA concentration. Also the apatite layer found
on SrHA samples seemed better adhered to the cement surface and thinner in comparison
to SrCaHA samples. Although, it is important to note that the apatite thickness
measurements on the SrHA/SrCaHA samples ranged from 5 – 20 μm in thickness,
indicating provision of a thick apatite layer for interaction with the surrounding tissue in
vivo. In order to determine whether the formation of apatite was present in the bulk of the
cements, we also looked at the cross-sections of the 10% SrHA and SrCaHA cement
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samples and did not find presence of apatite. This suggested that the apatite formation on
our SrHA and SrCaHA samples was limited only to the cement surfaces.
The formation of apatite on the cement surfaces is also known to promote cellular
attachment and spreading increasing the bioactivity. Xue et al. (79) investigated the in
vitro bioactivity of compacted discs of SrHA (10 mol% Sr substitution) powder and its
effect on cell attachment, proliferation, and differentiation by culturing osteoprecursor
cells. Their results suggested the presence of Sr stimulated cell differentiation and
enhanced alkaline phosphatase (ALP) and osteopontin expression indicating
mineralization. Ni et al. (76) studied a series of strontium substituted HA powders for
their structure, composition, dissolution behavior, and the effect on osteoblastic
differentiation, in which 0, 1, 5, and 10% calcium was substituted with strontium. They
cultured rat mesenchymal stem cells (MSCs) with the culture media containing Sr ions
released from the strontium-substituted HA powders. They suggested that 5-10 mole % Sr
substitution in HA enhanced osteogenic differentiation of MSCs. Most of the above
mentioned studies from literature have evaluated properties of strontium-substituted HA
nano powder with increasing amount of strontium substitution or have only evaluated
incorporation of one composition of SrHA nanopowder (10 % Sr substitution) into BisGMA resin cements. However, varying the percentage of strontium substitution in HA
powders being incorporated into PMMA bone cements have not been evaluated thus far.
A further study by Ni et al (92) conducted the MTT test and looked at the ALP activity,
mRNA expression and mineralization nodules of MSCs subjected to SrHA conditioned
media. They observed no differences in the osteoblast proliferation between groups, but
observed an increase in the effect for mRNA expression and mineralization nodules with 5
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and 10 wt % Sr substitutions. Recently, Zhang et al. (2) compared the effect of strontium
substitution (10, 40, and 100%) of HA on osteoblasts and found 10% SrHA powder group
had the best performance. They did not find osteoblasts on the 100% SrHA surface
indicating that higher substitutions of strontium may appear to be toxic to the cells. Even
though strontium substitution favors osteoblastic cell differentiation, the optimal
concentration of strontium remains divisive. In our study the 50 and 100% Sr substituted
HA microspheres were incorporated into the η-TSBCs and were not shown to differ in
their ability to form apatite on the cement surfaces at each concentration. Although we had
higher strontium substitutions in our HA microspheres, most of these particles are
expected to be embedded in the PMMA matrix with contact available primarily at the
cement surfaces for osteoblast cells. Thus, in such a case the higher substitution of
strontium might not essentially be toxic to the osteoblasts and would be an interesting
follow up study in order to evaluate the effect of varying strontium-substitution in HA
microspheres. The in vitro performance of the η-TSBCs containing SrHA and SrCaHA
microspheres in SBF is encouraging and future work would look at the in vivo bioactivity
and biocompatibility. The biomechanical evaluation of these cements is reported in the
next chapter.

4.5

Conclusions
This work demonstrated that addition of SrCaHA or SrHA microspheres to η-TSBCs
improved bioactivity in comparison to the control cements. Apatite formation was
observed on all of the SrHA/SrCaHA cement compositions irrespective of the amount of
strontium substitution in HA and the concentration of SrHA/SrCaHA microspheres.
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Addition of SrHA and SrCaHA microspheres provided good radiographic contrast
necessary for VP and KP applications, eliminating the need of adding an additional
radiopacifier. Apatite formation on cement surfaces was observed even at lower
concentrations of the SrHA/SrCaHA bioactive filler. Further investigation using osteoblast
cell cultures evaluating the effect of different strontium substituted HA microspheres in ηTSBC needs to be performed. This improvement in bioactivity makes the η-TSBC a good
alternative to the powder- liquid cements for VP/KP applications.
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Chapter 5
______________________________________________________________________________

5

Biomechanical evaluation of two-solution bone cements with strontium-substituted
hydroxyapatite microspheres

This chapter reports the effect of increasing concentration (0, 10, and 20 % wt/vol) and
strontium substitution of hydroxyapatite (HA) microspheres on the flexural, compressive,
and fracture toughness properties of two-solution bone cement (η-TSBC). The two different
types of hydroxyapatite microspheres used were partially (50 %, SrCaHA) and fully (100 %,
SrHA) substituted strontium-hydroxyapatite synthesized in our laboratory. Cements
prepared with SrHA/SrCaHA microspheres exhibited significantly higher compressive
strength than η-TSBC at increasing microsphere concentrations. The flexural properties of
the SrHA/SrCaHA cements decreased relative to the control η-TSBCs with increasing filler
concentrations, however, they were similar to the 20 % zirconium dioxide (ZrO2) containing
η-TSBC. Furthermore, no significant effect of cement composition or SrHA/SrCaHA filler
concentration was observed on the fracture toughness properties in comparison to control ηTSBCs. The filler composition (SrHA/SrCaHA) did not significantly affect the static
mechanical properties of the modified η-TSBCs at each concentration. The decrease in the
mechanical properties may be a consequence of the SrHA/SrCaHA microsphere
agglomeration. The fractured surfaces and crack-growth mechanisms were analyzed using
scanning electron microscopy (SEM). This study indicates that addition of higher
concentrations of SrHA/SrCaHa filler significantly affects the mechanical properties of two47

solution bone cements, while also bringing them closer to the mechanical properties of
human cancellous bone that may be advantageous.

5.1

Introduction
Acrylic bone cements have been used widely in orthopedic surgery to allow for fast
anchorage of the implant and a better distribution of physiological loads between the
prosthesis and the bone (25, 27, 37). Kyphoplasty and vertebroplasty procedures involve
percutaneous injection of bone cements under real time fluoroscopy image guidance into
fractured vertebrae, so the most desirable properties of cements for these applications are
high radiopacity, easy injectibility, appropriate mechanical properties resembling those of
non-osteoporotic vertebrae, and adequate interdigitation with the cancellous bone (5, 7, 35).
Radiopacity is achieved by addition of radio contrast filler, such as barium sulfate (BaSO4)
or zirconium dioxide (ZrO2), which are known in literature to cause alterations in the
biological and mechanical properties of cements (36). The effect of BaSO4 on the
mechanical properties of bone cements is contradictory, but most studies report deleterious
effects of adding BaSO4 on the mechanical properties of bone cements (93-98). Ginebra et
al. (96) showed that addition of 10 wt % BaSO4 to PMMA based cement lowered the
tensile strength, fracture toughness, and fatigue crack propagation resistance in comparison
to 10 wt% ZrO2 filler addition. Wang et al. (95) showed a similar decrease in tensile
strength and fracture toughness with addition of 10% BaSO4 to Simplex P cement. Vallo et
al. (99) reported that presence of BaSO4 and ZrO2 fillers improved fracture toughness of
PMMA cements by promoting interactions between the crack and second phase dispersion.
Deb et al. (98) concluded that the presence of the inorganic phase did not affect the tensile
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strength of acrylic cements. In comparison to the addition of BaSO4, radiopacifiers such as
ZrO2 seemed to have less detrimental effects on mechanical properties of bone cements due
to size and morphology of particles that allow for better integration within the PMMA
matrix (96). Rodrigues et al. (30) have shown recently that ZrO2 added to two-solution
cements up to concentrations as high as 20 % wt/vol had a less detrimental effect on their
static mechanical properties in comparison to BaSO4 . They also observed that when
BaSO4 was added to η-TSBCs, it affected the viscosity of the cements negatively as mixing
BaSO4 into solutions containing PMMA nanospheres led to the formation of a powdery
mixture with difficult handling and injectibility properties.
In view of these studies, alternative fillers and methods have been explored for
developing radiopaque as well as bioactive bone cements. Incorporation of bioactive
particles such as hydroxyapatite (HA) (53, 100, 101), strontium-substituted hydroxyapatite
(SrHA) (66, 70, 73), iodine (36), and glass particles (102), that allow for better integration
with the surrounding bone have been studied. Some studies have also concentrated on
addition of fibers to reinforce the cement (103, 104). Pourdeyhimi et al. (104) reinforced
PMMA cements with short ultra high molecular weight polyethylene fibers and studied
their fracture properties. They reported a significant reinforcing effect at a lower
concentration of fibers (1 wt %) and observed that beyond this concentration the fracture
toughness became insensitive to the increasing fiber content. The fiber reinforced cements
possessed increased stiffness but poor intrusion characteristics. Kim et al. (105) added up to
30 wt% of bone mineral particles to Zimmer Regular ® bone cement and observed a linear
decrease in the cement tensile strength with increasing amounts of bone particle despite of
the decreased percent porosity. Vallo et al. (102) incorporated different weight fractions
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(12 -50 wt %) of glass spheres (105 -210 μm in diameter) into a PMMA cement (Subiton,
Subiton Laboratories, Buesnos Aires, Argentina) and investigated the flexural, compressive
and fracture properties. They reported that the glass particles could be added upto 50 wt%
with significant increases in the flexural modulus and fracture toughness displaying a
reinforcing effect of the filler. However, they also observed through dynamic mechanical
analysis an increase in the residual monomer content with increasing glass filler
concentration, which could explain the increase in fracture properties and reduction in the
compressive strength reported. Incorporation of HA filler has been studied by various
groups. Kwon et al. (39, 106) performed in vivo studies with HA impregnated PMMA
cement with increasing HA concentration up to 30% wt and found that there was new bone
formation near the interface between the implant and surrounding bone as the amount of
HA filler increased. They also found the interfacial shear strength increased compared with
the cement without HA, and was significant when using 30% HA as filler.
The presence of HA not only promotes bone growth, but also modifies the mechanical
properties of the cement. However, the effect of HA on the mechanical properties of bone
cements is not clear. For example, Vallo et al. (101) tested the flexural, compressive, and
fracture toughness properties of PMMA cements with varying amounts of HA nano powder
and found an increase in the flexural modulus and fracture toughness when HA was added
to radiolucent cements. However, this increase was limited to concentrations up to 15 wt%
of HA, due to agglomeration of HA and increase in porosity at higher concentrations.
Serbetci et al. (107) reported that presence of HA up to 15 wt% in an acrylic based bone
cement increased the compressive strength and provided sufficient compressive fatigue
strength, but lowered the tensile properties. Morejon et al. (53) studied the effect of
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amount (0, 10, and 30 wt %) and type of HA incorporated into acrylic cement on the
compressive, flexural and fracture toughness properties. They observed that inclusion of
any type of HA increased the flexural modulus, but decreased the compressive and fracture
properties of the cement. However, the mechanical tests carried out by Kwon et al. (39)
showed a significant linear decrease in the flexural and diametrical tensile strength with
increasing HA concentration up to 30 wt %. Kobayashi et al. (51, 108) studied
compressive, bending, tensile strengths, and fracture toughness of three bioactive Bis-GMA
based cements containing apatite-wollastonite glass ceramic (AWC), HA, and tricalcium
phosphate (TCP), respectively, under wet conditions. They found that the compressive,
bending, tensile strengths, and fracture toughness of AWC were significantly higher than
those of HA and TCP. Cheung et al. (70) tested the compressive and bending strengths of
SrHA cement that they used in vivo in vertebroplasty applications, and have reported that
these cements had lower compressive and bending properties compared to the AWC
cements and current PMMA cements such as Simplex P (Stryker) and Palacos R (Zimmer).
These studies indicate that the mechanical properties of the bioactive cements are affected
by a number of factors such as matrix chemical composition, filler type, and filler
concentration.
In addition to having good bioactive properties, HA or SrHA-filled cements need
to have adequate static mechanical properties fulfilling the ASTM standards to be of
practical use. This work studies the static mechanical properties, such as compressive and
bending strengths, of two-solution bone cements (η-TSBC) filled with SrHA (100 %
strontium(Sr)-substituted HA) and SrCaHA (50% Sr-substituted HA) microspheres
prepared in the laboratory. The major mechanism for failure in cemented arthroplasties is
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gradual loosening of the cement at the bone-cement interface (37). Thus, fracture
toughness, which indicates the materials resistance to crack propagation, was also
determined. Since it was desired to incorporate the highest amount possible of
SrHA/SrCaHA microspheres to obtain higher bioactivity and bone growth promotion, the
effect of increasing filler concentration on the mechanical properties of η-TSBCs was also
evaluated. Furthermore, the fractured surfaces from the bending and fracture toughness test
specimens were studied under scanning electron microscopy (SEM) to determine the
fracture mechanisms.

5.2

Material and Methods

5.2.1 Preparation of SrHA/SrCaHA cements
The SrHA and SrCaHA microspheres (2-5 μm in diameter) were synthesized as
described by Zhang et al. (2, 83) and the atomic ratios of Sr/P and (Ca+Sr)/P were set as
1.67. The SrCaHA microspheres were prepared using the same hydrothermal procedure;
however in this case the [Sr / (Sr + Ca)] molar ratio was set as 0.5. The two-solution bone
cements containing cross-linked polymethylmethacrylate nanospheres (η-TSBC), used as
controls, were prepared as described by Rodrigues and co-workers (81, 82) at a polymer
to monomer ratio of 1:1 and cross-linked PMMA nanospheres to linear PMMA ratio of
1.5:1. For the preparation of η-TSBCs, benzoyl peroxide (BPO) (Aldrich), N, N-dimethyl
p-toluidine (DMPT) (Aldrich) and methylmethacrylate (MMA) (Fluka) were used as
received without further purification. The η-TSBCs were made up of two polymer
phases: 1) dissolved linear PMMA (Pl), and 2) dispersed cross-linked PMMA
nanospheres (Pb). These two components were massed and mixed together forming the
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powder phase (P). A part of the total volume of MMA was split and added to two
graduated cylinders, in which one was mixed with 1.25 g of BPO (1.25 g/100 ml of
MMA) and other with 0.7 ml DMPT (0.7 ml/100 ml of MMA). The two mixtures
BPO/MMA and DMPT/MMA were transferred to two polypropylene cartridges followed
by the addition of the powder phase and remaining MMA. The cartridges were sealed,
vigorously agitated by hand, and placed on a rotating drum mixer for 18 h. Following
mixing, the cartridges were stored upright at 4°C for 48 hours before use. In order to
prepare the η-TSBCs containing strontium substituted microspheres, the SrHA and
SrCaHA microspheres were added to the polymer phase at concentrations of 10 and 20%
wt/vol of MMA and the mixing procedure remained the same as described above for the
η-TSBCs.

5.2.2 Compression Testing
Cement cartridges were prepared at 0 (control η-TSBC), 10, and 20 % SrHA and
SrCaHA and injected into a Teflon mold consisting of cylindrical holes, each 6 mm in
diameter and 12 mm height, to make compression samples as per ASTM standard F45199a (30, 109). Five cylindrical samples for each composition were allowed to polymerize
in the mold for 1 hour followed by 24 hours of curing in air after removal from the mold.
All of the specimens were sanded with 600-grit sand paper and were visually inspected
for defects. Samples containing external voids or defects greater than 0.5 mm were
excluded. The specimens were subjected to compression testing in an MTS system
(Sintech 2G) with a 10 kN capacity load cell. The cylindrical samples were tested at room
temperature, in air, at a displacement rate of 0.05 mm/s and compressed to 50% strain.
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Stress and strain data were obtained by dividing the load and displacement by the crosssectional area and initial length of the specimens, respectively. Compressive strengths
and maximum strain to failure were measured. Compressive modulus was calculated
from the slope of the linear region of the stress-strain curve. Two-way ANOVA analysis
was applied at a level of significance of 95% to determine the effect of cement
composition and SrHA/SrCaHA filler concentration on each variable measured in the
compression test (compressive stress, compressive modulus, and strain to failure).

5.2.3 Flexural properties
Three point bend flexural tests were performed as per ASTM standard (D790-86
(110)) on five samples of each cement composition. The cement compositions tested
were η-TSBC containing 20% zirconium dioxide (ZrO2), and η-TSBC containing SrHA
and SrCaHA microspheres at concentrations 0 (control), 10, and 20% wt/vol. The
samples were polymerized in a rectangular Teflon mold and polished using sand paper
grits 240-600. The samples were on average 11.5 mm wide and 3 mm thick and were
tested using an MTS system (Sintech 2G) with a 10 kN capacity load cell. A crosshead
speed of 2.54 mm/min and span length of 40 mm were used. The flexural strength (σ),
flexural modulus (E), and maximum strain (ε) were calculated according to the following
equations (110)
σ =

ε=
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,

,

E=
where, P is the maximum load (N), L is the span length (mm), b is the sample width
(mm), d is the sample thickness (mm), D is the maximum deflection at the center of the
beam (mm), and M is the slope of the load/deflection curve (N/mm). The fractured
surfaces were studied using SEM to determine fracture mechanisms. Two-way ANOVA
statistical analysis was applied at a level of significance of 95% to determine the effect of
cement composition and filler concentration on each of the variable measured in the
flexural test (flexural strength, flexural modulus, and strain to failure).

5.2.4 Fracture toughness
Fracture toughness tests were performed, as per ASTM standard (E399-83(111)),
on five samples of each cement composition. The cement compositions tested were ηTSBC containing 20% zirconium dioxide (ZrO2), and η-TSBC containing SrHA and
SrCaHA microspheres at concentrations 0 (control), 10, and 20% wt/vol. Rectangular
samples were prepared with average width and thickness of 11.5 mm and 2.5 mm,
respectively. A notch was made using a slow speed diamond cut-off wheel and a razor
blade was used to impart the final sharp crack tip. The crack length (a) used was 45 to
55% of the width of the specimen. The samples were tested at room temperature on a
Sintech MTS system (model 2GT) using a crosshead speed of 2.54 mm/min and a span
length (L) of 40 mm. KIC (mode I plain strain fracture toughness) was calculated using
following equation (111)
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where, P is the maximum load (N), b is the samples thickness (mm), W is the sample
width (mm), and a is the crack length (mm). The fractured surfaces were studied using
SEM to determine fracture mechanisms. Two-way ANOVA analysis was applied at a
level of significance of 95% to determine the effect of cement composition and
SrHA/SrCaHA filler concentration on the fracture toughness.

5.3

Results

5.3.1 Compressive properties
Compression tests were performed to investigate the effect of addition of SrHA
and SrCaHA microspheres on the mechanical behavior of η-TSBCs as illustrated in
Figure 11. The compressive strength of SrHA and SrCaHA cements exceeded minimum
specification of 70 MPa (ASTM F451-99a (109)) for all compositions investigated.
Figure 11 shows an overall comparison between the compressive properties (compressive
strength, compressive modulus, and strain to failure) of the two different cements at
increasing concentrations of SrHA and SrCaHA microspheres. The SrHA and SrCaHA
cements presented significantly higher compressive strengths in comparison to the plain
η-TSBCs, as shown in Figure 11(a). This parameter increased significantly with
increasing SrHA/SrCaHA concentration up to 20% (p < 0.05). However, mean
compressive strengths of SrHA/SrCaHA cements were not significantly different at each
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concentration. The behavior of the compressive modulus for the two cement
formulations is illustrated in Figure 11(b). Similar to compressive strength, compressive
modulus of the SrHA and SrCaHA samples increased significantly (p < 0.05) with
increasing SrHA/SrCaHA concentration. However, compressive modulus of the 10%
SrHA/SrCaHA was not significantly different than the control cements. The type of the
microspheres added (SrHA/SrCaHA) in the two-solution cement did not significantly
affect the compressive modulus of the material at each concentration. The strain to failure
is shown in Figure 11(c) for the two cement formulations and η-TSBC. Strains to failure
of the η-TSBC and 10% SrHA/SrCaHA cements were not significantly different.
However, there was a significant increase (p < 0.05) in strain to failure with increasing
microsphere concentration. There was no effect of the type of microsphere on the overall
compressive properties of SrHA/SrCaHA cements considering the statistical analysis did
not indicate significant differences between SrHA/SrCaHA cements at each
concentration in the three parameters evaluated.

57

Figure 11. Compressive properties of two-solution bone cements prepared with increasing concentration of
SrHA and SrCaHA microspheres. (a) Compressive strength, (b) Compressive modulus, and (c) Strain to
failure. Cements prepared with SrHA and SrCaHA microspheres have significantly higher compressive
strength than η-TSBCs and the compressive strength increased significantly with increasing SrHA/SrCaHA
concentration (p < 0.05).

5.3.2 Flexural properties
The effect of addition of SrHA/SrCaHA microspheres on the flexural properties
of η-TSBCs is illustrated in Figure 12. The flexural properties are compared to the ηTSBC containing 20% ZrO2 radiopacifier. The flexural strength of η-TSBCs, Figure
12(a), did not change significantly with addition of SrHA/SrCaHA microspheres at 10%
wt/vol concentration and were similar to the flexural strength of 20% ZrO2 composition.
The flexural strength of SrHA/SrCaHA cements decreased significantly (p <0.05) at 20%
wt/vol composition in comparison to the control samples. However, no significant
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differences were observed between the flexural strengths at each concentration of
SrHA/SrCaHA. There was no significant effect of SrCaHA concentration on the flexural
modulus of the η-TSBC, as shown in Figure 12(b). No significant differences were
observed in the flexural modulus between the control, 20% ZrO2, and SrCaHA cements.
However, a significant decrease in flexural modulus (p < 0.05) was observed with
increasing SrHA concentration in comparison to control, SrCaHA and 20% ZrO2 cement
samples. Similar results were observed for strain to failure as shown in Figure 12(c).
There were no significant differences found in the strains to failure between the control,
SrCaHA, and 20% ZrO2 cement compositions at each concentration. A significant
increase (p < 0.05) in strain to failure was observed with increasing SrHA concentration.

Figure 12. Flexural properties of η-TSBC, and η-TSBC prepared at 10 and 20% SrHA/SrCaHA and 20%
ZrO2. (a) Flexural strength, (b) Flexural modulus, and (c) Strain to failure. The flexural strength reduced
significantly with increasing SrHA/SrCaHA concentration (p < 0.05). However, no significant differences
were observed between strengths of SrHA and SrCaHA cements and between 20% ZrO2 and
SrHA/SrCaHA containing cement compositions.
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Figure 13. SEM micrographs of the fractured surfaces after flexural testing of the following compositions:
(a) Controls (b) 20% ZrO2 (c) 10% SrCaHA (d) 20% SrCaHA (e) 10% SrHA (f) 20% SrHA.

The 20% SrHA composition had significantly higher strain than all of the
compositions. The strain to failure values for SrHA and SrCaHA were significantly
different (p < 0.05) at each concentration. The SEM micrographs in Figure 13(a-f) show
the morphology of the fracture surfaces of flexural samples tested to failure. The fracture
surface of η-TSBC, Figure 13(a), showed smooth mirror-like zones with striated areas,
which might be an indication of a slow stable crack growth. A homogeneous nano beadmatrix structure can be observed at higher magnifications, in which nanospheres are very
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close to each other. The fracture surface of 20% ZrO2 composition, Figure 13(b), showed
poor matrix-bead interface that allowed for crack branching. The ZrO2 microspheres
embedded in the matrix, debonded from the matrix creating pores in the 50-100 μm
range. The fracture surfaces of all the SrHA/SrCaHA compositions, Figure 13(c-f),
showed a very rough and chalky appearance due to SrHA/SrCaHA agglomerates
indicating zones with slow crack propagation and crack arrest. Figure 14 (a,b) shows
higher magnification SEM micrographs of fractured surfaces of 20% SrCaHA cements
that showed lower strains to failure indicating that this composition is more susceptible to
brittle failure. It can be observed that the regions where higher concentrations of
nanosphere were present appeared darker in comparison to the region containing SrHA
microspheres. These regions that have high concentrations of nanospheres and
microspheres are relatively devoid of PMMA matrix. It is hypothesized that these
regions of the cement are susceptible to brittle fracture and the inhomogeneous
distribution of PMMA nanospheres and SrHA microspheres likely contributes to the
lower strains at failure in these cements. In contrast, in regions of the fracture surface
where these particles are well dispersed, there is evidence of plastic deformation in the
PMMA matrix. The appearance of the fracture surfaces was consistent within each
cement type, independent of the SrHA/SrCaHA concentration.
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Figure 14. High magnification SEM micrographs of the fractured surfaces of (a) and (b) 20% SrCaHA
cements indicating ductile fracture where regions with higher concentration of nanospheres and depleted
matrix was observed. Black arrows indicated the regions having SrHA microspheres embedded in the
cement matrix (white region).

5.3.3 Fracture toughness
The effect of SrHA/SrCaHA microspheres on the fracture toughness of ηTSBC is presented in Figure 15. The results from Figure 15(a) showed that addition of
SrHA or SrCaHA microspheres at different concentrations did not significantly affect the
fracture toughness of the η-TSBCs. There were no significant changes in the stress
intensity factor (KIC) between all the compositions and 20% ZrO2 cements. The SEM
micrographs in Figure 15(b-g) show morphology of the fractured surfaces and crack
propagation in all of the fracture toughness samples tested to failure. The fractured
surfaces for the control samples, Figure 15(b), showed smooth regions at the crack
initiation followed by striated areas indicating slow crack growth. The fractured surfaces
of 20% ZrO2 samples, Figure 15(c), showed crack propagation around and not through
the ZrO2 beads/agglomerates, along with debonding of microspheres from the matrix
creating pores. All of the fractured surfaces of the SrHA and SrCaHA compositions,
Figure 15(c-g) and Figure 16 (a,b), also showed crack propagation around the
microspheres and not through the beads, in which the matrix-bead interface allowed for
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crack branching. The backscattered SEM micrograph of the 20% SrCaHA fractured
surface showed a non homogeneous distribution of SrCaHA particles, with some
dispersed particles along with some agglomerates in the matrix. However, cracks were
mainly observed to propagate through the nanosphere-PMMA matrix and around the
microspheres. Debonding of microspheres from the matrix was not observed, and thus no
evidence of porosity was seen with SrHA/SrCaHA compositions.

Figure 15. (a) Fracture toughness of η-TSBCs prepared at increasing concentration of SrHA and SrCaHA
microspheres. There was no significant effect of addition of SrHA/SrCaHA microspheres on the fracture
toughness of η-TSBCs. SEM micrographs of the fractured surfaces depicting the crack propagation in the
following cement compositions: (b) Controls (c) 20% ZrO 2 (d) 10% SrCaHA (e) 20% SrCaHA (f) 10%
SrHA (g) 20% SrHA.
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Figure 16. High magnification SEM micrograph of fractured (a) 10% SrCaHA and backscattered SEM
micrograph of fractured (b) 20% SrCaHA cement surfaces showing advancement of the main crack via
microcracks through the matrix around the SrCaHA beads/agglomerates.

5.4

Discussion
The effect of addition of SrHA/SrCaHA microspheres at varying concentrations was
evaluated on the mechanical properties of η-TSBC formulation. η-TSBCs containing
SrHA/SrCaHA microspheres presented significantly higher compressive strengths in
comparison to control η-TSBCs as illustrated in Figure 11. The compressive strength of
these two formulations increased significantly with an increase in SrHA/SrCaHA
concentration up to 20% wt/vol. The predominant mode of loading in spine in vivo is axial
compression, hence the measurement of compression strength values of the prepared
cements were important. The values of compressive strength reported here for all
formulations were higher than the minimum required by the ASTM regulations (70 MPa),
and were well within the reported values for commercial cements (77 to 150 MPa) (26).
There was no significant effect of the type of microspheres on the compressive strengths at
each concentration indicating that both SrHA and SrCaHA microspheres were capable of
increasing the compressive strength of the η-TSBC. Kobayashi et al. (108) incorporated
50, 70, and 80 % w/w of HA filler in Bis-GMA cements and investigated the compressive
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and bending properties of the cements. They reported compressive strength values as high
as 157 ± 4 MPa and 158 ± 9 MPa for their 50 and 70 % HA compositions, respectively.
Serbetci et al. (107) also observed an increase in the compressive strength of PMMA bone
cement from 96 MPa to 122 MPa with increasing HA concentration up to 14 wt %. They
concluded that further increase in filler concentration may lead to decreased compressive
properties, as HA particles distributed homogeneously in small quantities can behave as
load carriers leading to enhanced mechanical properties; however, an increase in HA
concentration may lead to their aggregation and non homogeneous distribution resulting in
poor adhesion to the matrix and decreased compressive strength. Furthermore, they
explained that the thermal expansion coefficient of HA particles was 10 times less than that
of PMMA and hence their volumetric changes post polymerization would not be similar.
After polymerization when both the materials shrink, the shrinkage of PMMA matrix
would be more than the shrinkage of HA particles, resulting in HA particles that are
trapped to be squeezed firmly in the PMMA matrix and causing a hoop stress to be formed
adjacent to the HA particles (107). This hoops stress would simulate a weak bonding
between HA particles and PMMA matrix and hence, during compressive load application
the interface between the two phases would act like a grain boundary resisting propagation
of crack. However, when a tensile load would be applied, the direction of the crack
propagation would be perpendicular to the direction of the hoop stress and the applied load,
wherein the hoop stress would help the crack edges to be separated. They concluded that
HA-containing cements were weaker in tension than in compression (107).
Measurements of the flexural properties of SrHA/SrCaHA cements (Figure 12)
revealed a decrease in the flexural strength of the η-TSBCs with increasing
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SrHA/SrCaHA microsphere concentration. The strain to failure of η-TSBC decreased
with addition of SrCaHA microspheres indicating that these compositions were more
susceptible to brittle failure. However, the SEM micrographs of the fractured
SrHA/SrCaHA surfaces also showed some ductile deformation. The fractured
SrHA/SrCaHA surfaces were rougher in comparison to the control cements, and
agglomeration of these microspheres was visible at higher concentrations and could be
one of the reasons for lower flexural strengths. A decrease in flexural modulus was also
observed with increasing SrHA concentration. It can be hypothesized that such a decrease
in modulus could be a result of incomplete polymerization, resulting in a lower glass
transition temperatures (Tg) and changes in the density of the polymerized samples. A
further evaluation of the effect of changes in polymerization reaction due to addition of
ceramic SrHA filler needs to be performed using differential scanning calorimetry in
order to measure the changes in the Tg. Also, density gradient columns can be used in
order to measure the changes in the densities of the cured samples. Furthermore, no
porosity was observed on the fractured SrHA/SrCaHA cement surfaces, indicating that
the introduction of SrHA/SrCaHA microspheres to the cement mixture did not cause
bubbling during polymerization giving rise to porosity. Incomplete polymerization could
result in a lower molecular weight for the PMMA matrix, along with an increase in the
residual monomer content; both of which could impact the mechanical properties of the
polymerized cements. An increase in the concentration of residual monomer in the
cement could have a plasticizing effect, thereby increasing the strain to failure of these
materials. However, a decrease in the molecular weight of the polymerized matrix will
ultimately result in cements with lower flexural strength. Thus these parameters need to
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be evaluated in future studies to better understand the mechanical behavior of these
cements. Agglomeration of the SrHA/SrCaHA microspheres results in poor integration of
these particles with the surrounding PMMA matrix. These regions may be more
susceptible to crack initiation, leading to an overall reduction in the mechanical
properties of these cements. Future efforts should be focused on obtaining polymerized
cements with a homogeneous distribution of both PMMA nanospheres and SrHA
microspheres throughout the PMMA matrix. A linear decrease in flexural properties with
increasing HA (irregular in shape, sized 420-1000 μm) concentration up to 30 wt% has
been observed by Kwon et al. (39). They incorporated HA powder at concentrations 0,
10, and 30 wt% into commercially available bone cement CMW1TM (CMW laboratories,
UK). Cheung et al. (70) tested SrHA nano powder (10% Sr substitution) containing BisGMA resin cement and observed a similar decrease in the flexural properties as
compared to commercially available PMMA cements. They reported a bending strength
around 31 MPa, similar to the flexural strengths observed in this study for SrHA/SrCaHA
containing η-TSBCs. They conclude that this decrease in bending strength and bending
modulus is beneficial as it would bring these values closer to those observed for human
cancellous bone and would reduce the fractures caused to the adjacent vertebrae due to
the problem of modulus mismatch between the bone-bone cement (70). Leong et al. (112)
also incorporated SrHA powder (10% Sr substitution) in a Bis-GMA resin blend at
concentration of 40 wt% and tested their compressive and bending properties. They too
report a reduced bending strength of 31.3 ± 3.2 MPa for SrHA-Bis-GMA cements in
comparison to the Simplex P (80 MPa) and Palacos R (79.6 MPa) commercial PMMA
cements tested. However, it is important to note that the flexural strengths of
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SrHA/SrCaHA η-TSBCs at each concentration were not significantly different to the
20% ZrO2 η-TSBC composition, indicating that these microspheres can be incorporated
into the η-TSBC to impart radiopacity and bioactivity instead of ZrO2 without any further
detrimental effect to their mechanical properties than has been observed by Rodrigues et
al. (30).
The fracture toughness (KIC) results are shown in Figure 15. There was no
significant effect of the addition of increasing concentration of SrHA/SrCaHA
microspheres on the fracture toughness of η-TSBC. Once again, there were no significant
differences between all compositions of SrHA/SrCaHA cements and 20% ZrO2 η-TSBC,
indicating that inclusion of these microspheres were not detrimental to the fracture
toughness properties of η-TSBC. Vallo et al. (101) studied the fracture toughness properties
of PMMA cements (Subiton, Subiton Laboratories) containing increasing concentrations
of HA and observed that the KIC values increased with increasing HA concentration up to
only 2.5 wt% HA inclusion (KIC value 1.62 MPa*m1/2). At higher concentrations of HA,
they observed that the fracture toughness (KIC) decreased monotonically with filler content.
The fractured SrHA/SrCaHA surfaces, examined under SEM in this study, appeared very
rough indicating considerable crack branching. At higher magnifications it was observed
on SrHA/SrCaHA surfaces that the crack propagation stopped once it found a bead or
agglomeration of these microspheres and continued around agglomerates. Despite a
reduction in KIC value in comparison to STSBC (1.73 MPa*m1/2), η-TSBCs containing
SrHA/SrCaHA microspheres studied here had KIC values similar to η-TSBC (0.8 ± 0.05 73
MPa*m1/2) and η-TSBC with 20% ZrO2 (0.71 ± 0.09 73 MPa*m1/2) and were within the
reported values for commercial cements (0.88 – 2.2 MPa*m1/2) (113, 114).
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However, due to the variation in type and concentration of bioactive fillers,
cement matrix composition, and the mechanical properties tested across various studies, it
is difficult to make a suitable comparison of our results to the values that have been
reported in literature. The SrHA/SrCaHA filled η-TSBCs tested here have adequate
mechanical properties to be used for vertebroplasty (VP) / kyphoplasty (KP) applications.
The variation in the amount of strontium-substitution in the SrHA microspheres
incorporated into η-TSBC did not have a significant effect on any of the static mechanical
properties tested. This was expected, as these microspheres had the same morphology, size,
and structure and differed only in their chemical composition that would pre-dominantly
have an effect on the bioactivity and antibacterial properties. Hernandez et al. (68, 74)
investigated compressive properties of PMMA cements containing SrHA nanopowder
(10% Sr) at concentrations of 10 and 20 wt% in air at room temperature as well as after
storing the specimens in SBF for a month at body temperature. They reported decreased
compressive strength and modulus for the SrHA cements stored in SBF for a month, due to
the plasticizing effect introduced by absorbed water. These observations necessitate a
follow up study that would determine changes in the cement mechanical properties under
physiological conditions after formation of apatite on their surfaces (through either being
soaked in SBF in vitro or after apatite formation in vivo).

5.5

Conclusions
Overall, this study evaluated the flexural, compressive, and fracture toughness
properties of η-TSBCs containing increasing concentrations of SrHA and SrCaHA
microspheres. Inclusion of SrHA/SrCaHA microspheres caused an increase in compressive
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strength and compressive modulus with increasing SrHA/SrCaHA concentration, which
makes them suitable for VP/KP applications. The flexural properties of SrHA/SrCaHA
cements at higher concentrations (20% wt/vol) were lower than η-TSBCs; however, the
obtained values were still similar to η-TSBC containing 20% ZrO2, indicating no further
detrimental effect on the η-TSBC properties while replacing ZrO2 with SrHA/SrCaHA in
order to impart radiopacity and improve bioactivity. No significant changes were observed
in the fracture toughness properties of η-TSBCs with incorporation of SrHA/SrCaHA
microspheres at increasing concentrations. The fractographic analysis revealed the presence
of areas of ductile fracture and microsphere agglomeration that could explain the decrease
of mechanical properties of SrHA/SrCaHA η-TSBCs. Further studies investigating the
effect immersion of SrHA/SrCaHA η-TSBCs in SBF at body temperature on their
mechanical properties need to be performed.
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Chapter 6
______________________________________________________________________________

6

In vitro evaluation of antibacterial properties of two-solution bone cements containing
strontium-hydroxyapatite microspheres
In this chapter, the antimicrobial properties of two-solution bone cement (η-TSBC)
containing strontium-substituted hydroxyapatite microspheres (Sr HA (100% Sr
substitution), SrCaHA (50% Sr substitution)) were investigated in vitro by culturing
Escherichia coli (E. coli) K12/pRSH103 biofilm. It was hypothesized that the capacity to
inhibit bacterial growth would increase with increasing concentrations of strontium
hydroxyapatite microspheres in η-TSBC and with increasing percentage of strontium
substitution in strontium hydroxyapatite microspheres. The concentration of the
SrHA/SrCaHA microspheres in the cements was varied at 0 (controls), 5, 10, and 20 %
w/vol. The cements containing 20% wt/vol of SrCaHA or SrHA microspheres exhibited the
greatest reduction in biofilm formation, 80% and 88% respectively, in comparison to the
plain control cements. However, there were no significant differences between cements
containing 20% wt/vol of SrCaHA and SrHA microspheres. At lower concentrations (5%
and 10% wt/vol), the cements containing SrCaHA microspheres reduced biofilm growth
more significantly than the cements containing SrHA microspheres. Additionally, the longterm effects of biofilm inhibition by cements containing 0, 10, and 20% wt/vol SrHA
microspheres were studied over a period of 14 days where the 10% and 20% compositions
were found to continually inhibit biofilm growth up to day 14.
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6.1

Introduction
Polymethylmethacrylate (PMMA) was one of the first biomaterials produced by the
chemical industry and it is still the most common material used in joint replacements and
orthopedic surgeries (12). However, most medical devices as well as biomaterials are
associated with 60-70% of all nosocomial infections (115, 116). The use of PMMA, like
any other biomaterial, entails a risk of attracting infectious microorganisms. Biomaterialassociated infections pose great surgical problems as infected implants generally require
surgical removal and since removal is not always easy, patients suffer severe discomfort
(117). These infections are a result of bacterial adhesion and subsequent colonization
leading to the inevitable biofilm formation at the implantation site (116). Buchholz (118)
first incorporated antibiotics in PMMA bone cements in order to reduce infection and many
studies have been performed since then with different materials and antibiotics (13). Apart
from gentamicin sulphate, antibiotics such as erythromycin, tobramycin, vancomycin, and
clindamycin have also been studied as additives for bone cements (13). Hernandez et al.
(119) studied the antibiotic release of ciprofloxacin (CFX) and vancomycin (VM) from
PMMA cements immersed in PBS for a period of 1 month. They observed a burst effect
for VM release, whereas no burst effect was observed for CFX and after a month in PBS,
CFX release was almost finished. Beeching et al. (120) conducted a comparative study
about persistence of antibacterial activity around antibiotic loaded PMMA bone cement
discs seeded on agar plates. The cement discs containing 2.5 wt% of cephalothin,
coumermycin, or fusidic acid antibiotics and inoculated with Staphylococcus aureus (S.
Aureus) bacteria produced inhibition zones for four to eight weeks. They concluded that
many factors such as stability and kinetics of antibiotics loaded, diffusibility of antibiotics
72

in agar, and the susceptibility of the indicator organism affect the size of the inhibition
zones. Several of these studies have however shown that antibiotic loaded PMMA
cements have relatively low drug elution property with various antibiotics (13).
Furthermore, concerns over the prolonged exposure of microorganisms to antibiotics such
as gentamycin, vancomycin, or erythromycin, in PMMA cements were raised, suggesting
that bacterial resistance could potentially be developed (14, 20, 21). Inclusion of yet
another filler material into the bone cement matrix also affects the cement mechanical
properties. Additions of antibiotic fillers to bone cements have been known to impact their
mechanical properties (12). Hernandez et al. (119) saw a decrease in flexural properties,
but no significant decrease in compressive properties of PMMA cements loaded with CFX
and VM. All of the above mentioned concerns raise the need for developing alternative
filler materials in place of antibiotics.
Recently, strontium substituted hydroxyapatite nano powder was used to coat
implant surfaces (3, 24) as an alternative to antibiotics. Strontium (Sr), a trace element
found in human body, is thought to be an antibiotic (4), effective in enhancing the
bioactivity (57) of biomaterials, and have potential in the treatment of osteoporosis (2, 60).
The addition of Sr as a dopant (1 wt% strontium oxide) to hydroxyapatite coating on
titanium implants also showed significant positive enhancement of human fetal osteoblast
cell proliferation and differentiation activity (24). PMMA bone cement containing
strontium substituted hydroxyapatite nano powder (SrHA, 10% Sr) has been reported to
have enhanced bioactivity due to release of strontium ions (Sr2+) which not only promotes
osteoblast proliferation, but also facilitates precipitation of apatite, thus increasing the
mechanical strength of the bone-implant interface (71, 74). Moreover, the antibacterial
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properties of the HA nanoparticles have been observed to improve after calcium is
partially or totally substituted by strontium indicating that introduction of strontium is a
major contributor in imparting antibiotic properties (1). Preliminary work on glass ionomer
dental cements (GICs) containing strontium oxide and fluoride fillers also revealed that
greatest antibacterial activity was observed with strontium oxide in comparison to fluoride
(4). However, they could not explain the mechanism by which strontium cements had
greater bactericidal action than fluoride. Deposition of strontium substituted apatites on
metal implant surfaces like titanium showed promising levels of microbial inhibition as
well as prolonged ability to reduce bacteria over a 30 day period (3). Gentamicin loaded
Bis-GMA cement containing SrHA nano powder (10% Sr) was evaluated as a drug
delivery system by Liu et al. (121). They confirmed that SrHA-Bis-GMA cements had
significant bactericidal action in comparison to PMMA cements as seen by the inhibition of
S. Aureus by release of gentamicin after 30 days. However, their study also focused on
investigating the mechanism of gentamicin elution from SrHA/Bis-GMA cements in
comparison to PMMA cements, and not on the antibacterial properties of strontium. There
is enough evidence in literature that strontium substituted HA powder does possess
bactericidal characteristics. However, due to limited number of published studies on the in
vitro antibacterial action of the Sr ion, the possible mechanism behind the bactericidal
action has not been understood completely. Also, the ability of SrHA bioactive filler to
possibly act as an antibiotic agent when added to acrylic bone cements for improving
bioactivity has not been tested or studied so far. In this study the antibacterial properties of
two-solution bone cements (η-TSBC) containing strontium-calcium hydroxyapatite
(SrCaHA, 50% Sr substitution) and strontium hydroxyapatite (SrHA, 100% Sr substitution)
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microspheres were investigated in vitro by culturing Escherichia coli K12/pRSH103
biofilm. The purpose of this study was to assess the possibility of introducing additional
antibiotic properties to two-solution bone cements along with radiopacity and bioactivity
by incorporation of SrHA/SrCaHA microspheres as a filler material.

6.2

Materials and Methods

6.2.1 Bone cement preparation
The SrHA and SrCaHA microspheres (2-5 μm in diameter) were synthesized as
described by Zhang et al.(2, 83) and the atomic ratios of Sr/P and (Ca+Sr)/P were set as
1.67. The SrCaHA microspheres were prepared using the same hydrothermal procedure;
however in this case the [Sr / (Sr + Ca)] molar ratio was set as 0.5. The two-solution bone
cements containing cross-linked polymethylmethacrylate nanospheres (η-TSBC), used as
controls, were prepared as described by Rodrigues and co-workers (81, 82) at a polymer
to monomer ratio of 1:1 and cross-linked PMMA nanospheres to linear PMMA ratio of
1.5:1. For the preparation of η-TSBCs, benzoyl peroxide (BPO) (Aldrich), N, N-dimethyl
p-toluidine (DMPT) (Aldrich) and methylmethacrylate (MMA) (Fluka) were used as
received without further purification. The η-TSBCs were made up of two polymer
phases: 1) dissolved linear PMMA (Pl), and 2) dispersed cross-linked PMMA
nanospheres (Pb). These two components were massed and mixed together forming the
powder phase (P). A part of the total volume of MMA was split and added to two
graduated cylinders, in which one was mixed with 1.25 g of BPO (1.25 g/100 ml of
MMA) and other with 0.7 ml DMPT (0.7 ml/100 ml of MMA). The two mixtures
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BPO/MMA and DMPT/MMA were transferred to two polypropylene cartridges followed
by the addition of the powder phase and remaining MMA. The cartridges were sealed,
vigorously agitated by hand, and placed on a rotating drum mixer for 18 h. Following
mixing, the cartridges were stored upright at 4°C for 48 hours before use. In order to
prepare the η-TSBCs containing strontium substituted microspheres, the SrHA and
SrCaHA microspheres were added to the polymer phase at concentrations of 5, 10, and
20% wt/vol of MMA and the mixing procedure remained the same as described above for
the η-TSBCs. The cements were then injected into square molds (0.5 inch in length and
1mm in thickness) and circular disk molds (6 mm diameter and 1 mm in thickness), and
allowed to polymerize for the casting of samples for the antibacterial tests.

6.2.2 Antibacterial tests: 24 hours and long-term
E. coli K12 strain RP437/pRSH103 from the study by Hou et al. (122) was used
to study the antimicrobial properties of the bone cements. The strain was labeled with a
constitutive Ds-Red Express (BD Franklin Lakes, NJ) fluorescent protein. An overnight
culture of E. coli RP437/pRSH103 was grown in Luria-Bertani (LB) medium containing
1 g/L bacto-tryptone, 5 g/L yeast extract and 10 g/L sodium chloride in deionized water.
Tetracyline (10μg/ml) was added as a supplement to help maintain the plasmid
pRSH103. The culture was incubated on an orbital shaker at 200 rpm at 37°C in the dark
(Orbit Shaker Model 3520, Lab-line Instruments, Melrose Park, IL). Prior to inoculation,
all of the cement samples were sterilized with ethanol, dried with a sterile 0.2 μm air
filter, and placed in a Biological Safety Cabinet (Purifier Logic 34600 Series, Labconco,
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Kansas City, MO) for 20 minutes under a UV light source. Following sterilization, three
samples from 0, 5, 10, and 20% SrHA and SrCaHA cement compositions were placed in
sterile petri dishes containing 20 ml of sterile LB medium with 10μg/ml tetracycline. The
optical density at 600 nm (OD600) of the overnight culture was measured with a Genesis 5
spectrophotometer (Spectronic Instruments, Rochester, NY) and the dishes were
inoculated with the overnight culture at an OD600 of 0.05. The petri dishes were then
placed in an incubator at 37°C in the dark without shaking for 24 hours.
Following incubation for 24 hours, the cement samples were gently washed three
times with 0.85 % sodium chloride buffer to remove planktonic cells. The samples were
then analyzed for biofilm surface coverage (%) using an Axio Imager M1 fluorescence
microscope (Carl Zeiss MicroImaging GmbH, Göttingen, Germany) with a mercury
vapor shot-arc lamp at 558 nm (HBO 103 W/2, OSRAM GmbH, Augsburg, Germany).
At least five images were randomly taken of each bone cement sample and control,
creating 15 images of each composition. The biofilm surface coverage (%) was
calculated from the images using the COMSTAT software written on the MATLAB
platform (123). Additionally, the long-term effects of biofilm inhibition by cements
containing 0, 10, and 20% wt/vol SrHA microspheres were studied over a period of 14
days. In this study, triplicate samples were analyzed on day 1, 6, 10 and 14. The samples
were transferred daily to new petri dishes containing fresh LB media supplemented with
10 μg/ml of tetracycline. The culture was inoculated daily with cells from overnight
culture in which the cell concentration was adjusted to the OD600 of 0.05. The samples
were analyzed for biofilm surface coverage, at each time point, as described above. The
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statistical analysis for percentage of biofilm surface coverage was performed using oneway ANOVA with a Tukey post-hoc test at a level of significance of 95%.

6.2.3 Antibacterial inhibition zone test
Antibacterial activity was also evaluated using the agar gel inhibition zone
method, which has been employed previously (1, 4, 120). The test bacteria was E. coli
K12 strain RP437. Sterile LB Agar medium containing 1 g/L bacto-tryptone, 5 g/L yeast
extract, 10 g/L sodium chloride, and 15 g/L agar in deionized water was poured into
plates. The agar was allowed to gel overnight and the agar plates were then stored at 4°C
before use. The E. coli culture was incubated on an orbital shaker at 200 rpm at 37°C in
the dark for 16 hours (Orbit Shaker Model 3520, Lab-line Instruments, Melrose Park, IL).
The optical density at 600 nm (OD600) of the overnight culture was measured with a
Genesis 5 spectrophotometer (Spectronic Instruments, Rochester, NY). The inoculum
suspension from the overnight culture was distributed evenly over the surface of the LB
agar gel plates at an OD600 of 0.05. All of the cement samples were sterilized with
ethanol, dried with a sterile 0.2 μm air filter, and placed in a Biological Safety Cabinet
(Purifier Logic 34600 Series, Labconco, Kansas City, MO) for 20 minutes under a UV
light source. Following sterilization, three cement disc samples of 0, 10, and 20% SrHA
and SrCaHA compositions were placed tightly onto the agar gel plates inoculated with E.
coli and incubated at 37°C for 24 hours. In addition to this, three 20% SrHA discs having
SrHA powder on their surface and three 20% SrCaHA discs having SrCaHA powder on
their surfaces were also placed onto the agar gel plates and incubated at 37°C for 24
hours. The SrHA/SrCaHA powders were used on the cement surfaces to determine
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whether contact inhibition is the primary mode of bacterial inhibition observed in these
cement compositions. Disc diameters were measured and the size of the inhibition zone
was calculated as follows:
Size of the inhibition zone (mm) = (diameter of zone of inhibition – diameter of the disc) / 2

If the inhibition zone was less than 5-7 mm, the test inhibitor could be determined to have
the antibacterial property at the condition of static contact with the bacteria. The
statistical analysis for size of the inhibition zone was performed using one-way ANOVA
with a Tukey post-hoc test at a level of significance of 95%.

6.3

Results

6.3.1 24 hour antibacterial study
The antibacterial activities of the SrHA and SrCaHA containing cements were
evaluated by analyzing E.coli biofilm formation on these materials, after 24 hours, using
fluorescence microscopy. To provide a quantitative comparison of biofilm growth, the
images were analyzed with COMSTAT and the percentage of biofilm coverage was
calculated and plotted as shown in Figure 17(a). Antibacterial activity of the SrCaHA and
SrHA cement was clearly confirmed by growth inhibition of E. coli in Figure 17(b-h).
Figure 17(a, e, h) showed that the 20% SrHA and 20% SrCaHA composition exhibited
significantly higher (p < 0.05) reduction in biofilm formation, 80% and 88% respectively,
in comparison to the plain control cements. A linear decrease (r2 =0.99) in biofilm surface
coverage was observed with increasing SrHA microsphere concentration, as expected.
However, the biofilm surface coverage for 5% SrHA composition was not significantly
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different from the control cements as also observed from Figure 17(a, b-d). The 10%
SrHA samples had a 2.53 ± 0.56 % surface coverage, which was a 33% reduction in
biofilm growth compared to the control cement. The surface coverage on 5% and 10%
SrCaHA composition was not significantly different from each other (Figure 17(f, g)),
although it was significantly different from the control and the 20% SrCaHA samples (p
< 0.05). At lower concentrations (5% and 10% wt/vol), the cements containing SrCaHA
microspheres reduced biofilm growth more significantly (p < 0.05) than the cements
containing SrHA microspheres.

Figure 17. Antibacterial study with E.coli for 24 hours. (a) Graphical representation of the biofilm surface
coverage (%) as a function of the concentration of SrHA and SrCaHA filler. The 20% SrHA and SrCaHA
compositions showed the strongest biofilm inhibition compared to the controls. A significant linear
decrease in biofilm coverage was observed with increasing concentration of SrHA filler. Fluorescence
micrographs of E.coli biofilm formation on (b) Controls, (c) 5% SrHA, (d) 10% SrHA, (e) 20% SrHA, (f)
5% SrCaHA, (g) 10% SrCaHA, (h) 20% SrCaHA samples (all at 20X magnification). Maximum biofilm
coverage is observed on control, 5% SrHA, and 5% SrCaHA samples.
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6.3.2 Long-term antibacterial tests
In order to evaluate the long-term inhibition of biofilm formation, the 10% and
20% SrHA samples were challenged with E.coli RP437 pRSH103 in LB medium for
varying periods of time (up to 14 days). Figure 18(a) showed that the 20% SrHA
composition was successful in continually inhibiting biofilm growth until day 14 in
comparison to the control samples. After incubation for 1 day, only several attached cells
could be seen on the 20% SrHA samples (Figure 18(b)). In contrast, the control and 10%
SrHA samples were extensively covered by E.coli biofilm. The 10% SrHA samples
significantly (p < 0.05) reduced the biofilm coverage up until day 6 (Figure 18(c)), after
which there were no significant differences observed in biofilm coverage in comparison
to the control cements. When incubated for 14 days, the 20% SrHA surface still had only
11.99 ± 1.71% biofilm coverage, while the surface coverage on the control and 10%
SrHA was 21.23 ± 3.45% and 16.00 ± 3.61%, respectively. E.coli clusters were apparent
on both, control and 10% SrHA samples, at day 14 (Figure 18(e)) covering the entire
surface of the cements.
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Figure 18. Long-term antibacterial study. (a) Graph of the E. coli biofilm surface coverage (%) as a
function of time in culture. The 20% SrHA samples showed continued significant biofilm inhibition up till
day 14 as compared to controls. The fluorescence micrographs of E.coli biofilm formation on controls,
10% SrHA, and 20% SrHA samples on (b) day 1 (c) day 6 (d) day 10 and (e) day 14 (all at 20X
magnification). The least amount of biofilm growth was visible on the 20% SrHA samples on day 14.

6.3.3 Inhibition zone test
The results from the inhibition zone test are shown in Figure 19(a-h). The results
demonstrated that none of the inhibition zones of SrHA/SrCaHA cements to the test
bacteria were more than 7 mm. The largest inhibition zones were observed with the
cement discs containing SrHA/SrCaHA powder on their surfaces (Figure 19(g,h)). Figure
19(a) indicated that there were no significant differences in the size of the inhibition
zones between different SrHA and SrCaHA cement compositions. Each cement
composition exhibited some degree of antibacterial activity, although it was observed to
be the greatest for 20% SrCaHA cement having SrCaHA powder on its surface (p <
0.05).
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Figure 19. Antibacterial inhibition zone test. (a) Graph of the size of the inhibition zone (mm) as a function
of cement composition. Antimicrobial activity was the greatest in the case of cements that had
SrHA/SrCaHA powder on their surface indicating that contact inhibition was the primary mode of bacterial
inhibition. Zones of inhibition produced after overnight incubation at 37°C of SrHA and SrCaHA
containing cement discs on supplemented LB agar seeded with E.coli biofilm, (b) Controls, (c) 10% SrHA,
(d) 20% SrHA, (e) 10% SrCaHA, (f) 20% SrCaHA, (g) SrHA powder on 20% SrHA cement surface, and
(h) SrCaHA power on 20% SrCaHA cement surface.

6.4

Discussion
The SrHA and SrCaHA cements were observed to successfully inhibit biofilm
formation. However, as expected, higher concentrations (20% wt/vol) of SrHA and
SrCaHA cements were the most effective in reduction of biofilm coverage. A linear
decrease in biofilm growth was observed with increasing SrHA concentration indicating
that the bactericidal action was dependent on the amount of SrHA microspheres
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incorporated. The results of this study agree with previous observations that substitution of
strontium in hydroxyapatite used as a coating on implants can improve their antibacterial
properties (1, 3, 4, 24, 76, 121). The 5% and 10% SrCaHA samples were found to inhibit
biofilm formation more significantly than the 5% and 10% SrHA cements, while the 20%
SrCaHA and 20% SrHA samples provided similar levels of biofilm inhibition. This may
suggest that the calcium had an additive effect on the antimicrobial properties of strontium.
A study by Ni et al. (71, 75) has evaluated the performance of non-acrylic strontium
hydroxyapatite bone cement in vivo, and observed that the presence of 10% strontium
substitution in hydroxyapatite added to the cement increased the amount of calcium in the
serum by about 17% compared to plain bone cements. Also, the binding of biofilms to
fibrinogen/fibrin has been shown to be inhibited by calcium ions (124) implying calcium
could have a synergistic role in inhibiting biofilm formation. The mechanistic action of Sr2+
on bacteria is less well understood than that of silver (Ag). Little is currently known with
respect to bacterial resistance to strontium, due to limited number of published studies on
the in vitro or in vivo antibacterial applications of the ion. Based on the previous studies (1,
3, 24) testing the bactericidal action of SrHA nano powders, we suggest two possible
mechanisms by which strontium could inhibit bacterial growth: 1) by contact inhibition,
upon static contact with SrHA/SrCaHA microspheres on the cement surface, 2) by elution
of Sr2+ ions into the surrounding physiological media via dissolution of SrHA/SrCaHA
microspheres available at the cement surface. Preliminary work by Guida and co-workers
(4) on glass ionomer cements that were modified with strontium and fluoride ions, for
dental applications, suggested that the antibacterial activity was greatest in the case of
cements that contained strontium oxide. This study also indicated that the antibacterial

84

effect was associated more with the release of strontium ions than fluoride ions. Lin et al.
(1) studied the antibacterial properties of hydroxyapatite along with fully and partially
substituted strontium hydroxyapatite powders and concluded that SrHA and SrCaHA
nanoparticles had higher antibacterial ratio compared to pure HA indicating that
antibacterial properties improved after calcium had been partially or totally substituted.
This study suggested that the reason behind improved antibacterial properties might be due
the increased solubility of SrHA and SrCaHA after strontium substitution resulting in the
release of more antibacterial strontium ions to inhibit the test bacteria. In our 24 hour study,
results suggested bacterial inhibition primarily due to contact with the SrHA/SrCaHA
microspheres exposed at the cement surfaces. However, the long-term evaluation of the 10
and 20% SrHA cement surfaces revealed continued inhibition of E. coli bacteria up to 14
days in culture in comparison to control cements, indicating possible elution of Sr ions into
the culture media. The least biofilm coverage was observed on the 20% SrHA samples after
14 days in culture. However, the observed OD600 values ranging from 0.590 to 0.895
indicated that the cells in the petri dishes were continuously growing. This demonstrated
that leaching of strontium from SrHA /SrCaHA microspheres into the media was not very
significant.
O’Sullivan and co-workers (3) have studied the effect of deposition of strontium
and silver doped apatite onto titanium surfaces and observed promising levels of initial
bacterial inhibition from both the surfaces, with strontium showing a prolonged ability to
reduce bacteria numbers over a 30-day period. Their study was the first to suggest that
direct contact with the coated substrate surfaces is the major reason of the antibacterial
performance and anticolonizing activity. Moreover, their study also suggested that the
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beneficial effect of Sr2+ ions on osteoblast cells created a possibility to produce a surface
which inhibits microbial colonization while simultaneously promoting osseointegration (3).
Our antibacterial inhibition zone test results using agar gel plate diffusion assay also
showed that the antibacterial activity was more pronounced when cement samples had
SrHA/SrCaHA microsphere powders readily accessible at the cement surface. The cement
compositions where the SrHA/SrCaHA powders were not added on top of the cement
surfaces showed comparatively smaller biofilm inhibition zones. All the inhibition zones
observed for different cement compositions in this study were less than 7 mm indicating
that the primary mode of bacterial inhibition was static contact with SrHA/SrCaHA
microspheres or SrHA/SrCaHA powders available at the cement surface. The inhibition
zones were expected to be larger than 7 mm if strontium elution and diffusion through agar
gel had occurred. On the basis of comparisons of the antimicrobial activity of strontium
substituted apatite powders from literature, the data presented in our study suggests that the
direct contact of microbes with the SrHA/SrCaHA microspheres present at the cement
surface maybe a significant contributing factor for the antibacterial activity of the cement
samples, as dissolution of Sr from these particles in the cement matrix is difficult. Future
work would include determining the exact metabolic pathways of bacterial inhibition by
strontium substituted hydroxyapatite microspheres. Also, in order to provide a better
understanding of how these cements may perform in vivo, the performance of these
cements need to be evaluated in vitro in the presence of serum or other common matrix
adhesion proteins that are typically present in vivo at the implant site. The ability to test the
bone cements with Staphylococcus aureus and Staphylococcus epidermidis, which are
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commonly found bacteria in orthopedic infections, would help in determining whether the
antibacterial inhibition can be sustained with more virulent strains.
6.5

Conclusions
It can be concluded that the antibacterial properties of η-TSBCs improved significantly
upon addition of strontium substituted HA (SrHA/SrCaHA) microspheres. This work also
validates the possibility of employing strontium-substituted HA microspheres as alternative
antibiotic fillers for acrylic bone cements. The 20% SrHA and SrCaHA composition were
observed to be the strongest inhibitors of E. coli biofilm formation indicating that the
antimicrobial properties were dependent on the concentration of SrHA/SrCaHA
microspheres incorporated into the cement. Although it is not possible to fully explain the
mechanism by which cements containing SrHA/SrCaHA fillers exhibit antibacterial
properties, this work provides evidence that static contact of the test bacteria with
SrHA/SrCaHA microspheres is an important contributing factor. Development of η-TSBCs
containing strontium substituted microspheres provides a useful material for controlling
biofilm infections, with promising applications in joint arthroplasties, vertebroplasty,
kyphoplasty, and other orthopedic surgeries.
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Chapter 7
______________________________________________________________________________

7

Summary
The overall objectives of this work have been accomplished as discussed in the
different sections of this dissertation. Foremost, SrHA/SrCaHA microspheres were
successfully fabricated with varying amounts of strontium substitution (50 % and 100 %) in
HA. The introduction of SrHA/SrCaHA microspheres in η-TSBCs at varying concentrations
allowed for evaluation of their efficacy in improving a combination of cement properties,
such as radiopacity, bioactivity, and antibacterial properties. It has been shown previously
that SrHA nano powder (10% Sr substitution) provides radiopacity (66, 68, 75, 87) when
included in bone cements, as Sr falls under the same group of elements such as barium and
calcium used in commercially available radiopacifiers. Our work also reports a linear
increase in the contrast of η-TSBC with increasing concentrations of SrHA/SrCaHA
microspheres. Thus, the goal of introducing SrHA/SrCaHA microspheres in η-TSBCs for
improving bioactivity additionally allowed for complete removal of ZrO2 radiopacifier used
previously by Rodrigues et al. (82) to impart radiopacity in η-TSBCs. This was thought to
be advantageous as many studies have reported deleterious effects of radiopacifiers, such as
BaSO4 and ZrO2, on the mechanical properties of acrylic cements (94-97). Secondly, all of
the compositions of SrHA/SrCaHA containing η-TSBCs evaluated for bioactivity using
SBF have been shown to have the capacity to form apatite on their cement surfaces.
Therefore, both the partially and totally substituted SrHA microspheres proved successful in
improving the bioactive properties of acrylic η-TSBCs. Thirdly, introduction of
SrHA/SrCaHA microspheres in η-TSBC at higher concentrations was shown to reduce
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biofilm formation through bactericidal action of Sr in comparison to control cements. Most
commercial cement formulations used currently would require addition of an antibiotic,
such as gentamicin sulfate, in order to prevent bacterial infections prevalent during
orthopedic surgeries (13, 19, 120). Addition of antibiotics to acrylic bone cement has been
studied extensively and is reported to further reduce the mechanical properties of PMMA
cement (12, 119). Therefore, the feasibility of completely substituting the ZrO2 radiopacifier
in η-TSBCs with a single bioactive filler that could provide good radio contrast, bioactivity,
and antibacterial properties all at the same time provides a cost-effective and superior
cement formulation in comparison to the current commercial cement formulations that
require addition of different fillers to achieve each of these individual properties.
SrHA nanopowder with 10 mol% strontium substitution in HA was fabricated by
Li et al. (66) and was introduced by their group into Bis-GMA resin cements as a bioactive
filler. They reported improved in vitro as well as in vivo bioactivity of Bis-GMA cements.
The bioactive properties of Bis-GMA cement consisting of this SrHA nanopowder has been
studied extensively thereafter by Ni et al. (73, 75, 76, 88, 92) using in vitro and in vivo
models. Incorporation of HA powder as bioactive filler material has been investigated
largely in PMMA based bone cement formulations (38, 39, 47, 52, 125, 126). However,
only Hernandez et al. (68, 74) thus far has investigated the incorporation of strontium
substituted hydroxyapatite (10% Sr substitution) as a potential bioactive filler material in
acrylic based (PMMA) bone cement. Hernandez et. al (74) observed improved ability of
apatite formation only on surfaces containing 20 wt% SrHA nanopowder that had been
treated with MMA solution. However, we observed apatite formation on our η-TSBC
compositions containing SrHA/SrCaHA microspheres even at lower concentrations (10%
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wt/vol), which was promising. Most of the above mentioned studies employing SrHA
nanopowder in bone cements for imparting bioactivity evaluated only 10 mol% strontium
substitution in HA. SrHA nanoparticles with 50 and 100% Sr substitution have been
evaluated for their antibiotic properties in vitro by Lin et al. (1). However, only Liu et al.
(121) incorporated SrHA nanopowder (10% Sr) into a bone cement (Bis-GMA resin) along
with gentamicin to investigate SrHA-Bis-GMA as a drug delivery system. They did not
however investigate the potential of SrHA to act as an antibiotic filler. In our work, not
only did we introduce SrHA microspheres (2-5 μm in diameter) into PMMA cement
matrices for improving bioactivity, but we also varied the amount of strontium substitution
(50% and 100% Sr) in order to evaluate the effect of higher substitution on bioactivity and
antibiotic properties of η-TSBCs. Our study reports no significant effect of strontium
substitution or SrHA/SrCaHA concentration on the ability of SrHA-η-TSBCs to form
apatite on their surfaces. However, the increase in strontium substitution did have a
significant effect on the antibiotic properties of SrHA-η-TSBCs. SrCaHA-η-TSBCs were
observed to have greater biofilm inhibition in comparison to SrHA-η-TSBCs at lower
concentrations. At higher SrHA/SrCaHA concentration both the cement compositions
provided similar bioactivity and antibiotic properties. Thus, η-TSBC composition containing
20% SrHA/SrCaHA was believed to have optimal antibiotic and bioactive properties. We
also concluded that the primary mechanism of bacterial inhibition observed on
SrHA/SrCaHA η-TSBCs was via contact inhibition, upon direct contact of bacteria with
SrHA/SrCaHA microspheres available at the cement surfaces.
The 20% SrHA/SrCaHA composition was also shown to have adequate compressive,
flexural and fracture toughness properties required for VP/KP applications. It was observed
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that inclusion of SrHA/SrCaHA up till 20% wt/vol did not have any further detrimental
effect on the static mechanical properties of η-TSBC in comparison to η-TSBCs containing
20% wt/vol ZrO2 filler. Serbetci et al. (107) has shown reduction in mechanical properties
due to increased porosity and agglomeration of HA nanopowder at higher concentrations.
The SEM micrographs of the fractured surfaces of 20 % SrCaHA and SrHA cements after a
fracture toughness test, are shown in Figure 20 (a,b) and 20 (c,d), respectively. The
backscattered SEM micrographs of 20 % SrHA/SrCaHA cements (Figure 20 (b) and (d))
showed that the microspheres were not dislodged from the cement matrix indicating no
porosities were caused. The crack was observed to propagate around the SrHA/SrCaHA
microspheres or agglomerates rather than through the microspheres. This result was
promising, as SrHA/SrCaHA microspheres can be subjected to surface treatments in the
future studies to improve interaction with the PMMA nanospheres resulting in improved
adhesion and integration with the PMMA matrix and their fracture toughness properties.

Figure 20. SEM micrographs of fractured surfaces of η-TSBCs containing (a) 20% SrCaHA and (c) 20% SrHA
microspheres subjected to fracture toughness testing. Backscattered SEM micrographs of the η-TSBCs
containing (b) 20% SrCaHA and (d) 20% SrHA microspheres. The black arrows indicate the crack propagation
around the SrHA/SrCaHA microspheres or agglomerates rather than through the microspheres.
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Most of the studies evaluating SrHA filler use SrHA nanopowder for
incorporation into cements. In this study, we fabricated SrHA/SrCaHA microspheres using
the hydrothermal synthetic route suggested by Zhang et al. (127). Zhanglei et al. (83) and
Zhang et al. (127) developed Sr-doped HA microspheres that have excellent
photoluminescent properties without using expensive rare earth ions, in order to use them as
a new, efficient, and low-cost blue luminescent material. Their as-obtained 20% SrHA
microspheres were shown to have the highest photoluminescence by a bright blue emission
from 350 to 570 nm centered at 424 nm wavelength under UV light excitation. The
SrHA/SrCaHA microspheres that were synthesized in this study via the same synthetic route
thus also possess the added ability to emit a blue emission peak when exposed to a UV light
or under a DAPI filter on the fluorescence microscope (having an excitation in the same
range as UV light). Therefore, when we looked at the cement surfaces containing
SrHA/SrCaHA microspheres under a fluorescence microscope using a DAPI filter, we could
see the SrHA/SrCaHA particles as blue spheres or agglomerates. This property of
SrHA/SrCaHA microspheres was utilized to look at the distribution of these particles on the
cement surface, which was observed to be heterogeneous throughout the cement surface.
This property of the SrHA/SrCaHA microspheres can be beneficial to our future work. Our
preliminary cell cytotoxicity studies on 10% SrHA/SrCaHA η-TSBC (not reported here)
using MC3T3-E1 pre-osteoblast cells revealed that we could not only use the green (calcein
AM dye) and red (ethidium homodimer 1 dye) fluorescence from the live-dead kit to
observe the live-dead cells, but also use blue (DAPI) fluorescence to simultaneously observe
the location of the SrHA/SrCaHA microspheres with respect to the attached cells. Thus, it
was possible to acquire a composite image with the green (live cells), red (dead cells), and
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blue (SrHA/SrCaHA microspheres) fluorescence as shown in Figure 21 (a,b). It can be
observed from Figure 21(a) that most of the dead cells (red) were found to be present in the
areas devoid of the SrHA/SrCaHA microspheres (white arrows), whereas most of the live
cells (green) were present on top of the SrHA/SrCaHA microspheres as indicated by white
arrows in Figure 21 (b). This preliminary result also confirmed that SrHA/SrCaHA particles
are biocompatible and would promote osteoblast cell attachment. This property of
SrHA/SrCaHA microspheres can prove beneficial in the future studies as a tool to look at
the interaction of osteoblasts with η-TSBC surfaces containing SrHA/SrCaHA
microspheres.

Figure 21. Fluorescence micrographs of MC3T3 preosteoblast cells cultured on η-TSBCs containing (a) 10%
SrHA and (b) 10% SrCaHA microspheres. Red fluorescence = dead cells, green fluorescence = live cells, blue
fluorescence = SrHA/SrCaHA microspheres. The white arrows in (a) indicate dead cells on areas devoid of
SrHA, while white arrows on (b) indicate live cells on top of the SrCaHA microspheres. 10X magnification.

In this work, the variation in strontium substitution did not significantly affect the
mechanical or bioactive properties, but significantly affected the antibiotic properties of ηTSBC containing SrHA/SrCaHA microspheres. This indicates that the cement formulations
can be modified or altered depending on the requirements of the applications. For example,
in the case of cemented arthroplasties where better interfacial strength between bone and
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implant is required for long-term stability of prosthesis, both 20% SrHA and SrCaHA
formulations could find applications. Whereas, for the case of treating battlefield wounds
where preventing infections is a priority along with fracture stabilization, 20% SrCaHA
formulation exhibiting superior bioactive as well as antibiotic properties could find
applications.
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Future Work
The results presented in this work consisted of several advantages involving the
η-TSBC formulation, right from the synthesis of SrHA/SrCaHA microspheres to the
development of η-TSBCs containing these microspheres. The findings of this study will not
only serve as a platform for continued improvements in order to better understand properties
of these cements, but also provide a basis for solutions to the current drawbacks introduced
with these innovations.
Some of the areas that need more in depth study in follow up projects are:
1. Study of initial in vitro interaction of osteoblasts with cement surfaces containing
SrHA/SrCaHA microspheres:
The material surface and topography influences cell reaction through changes in
cell cytoskeleton and also dictates the cell attachment, morphology, and viability. It has
been reported that bone formation is dependent on the number of cells and the cell
number is largely dependent on cell adherence and proliferation (48). Thus, initial
recruitment of cells on a material surface is of great importance to terminal
differentiation of cells in contact with a material. An in vitro tissue culture model needs
to be developed to evaluate the biological response on η-TSBC versus η-TSBC
containing SrHA/SrCaHA microspheres. Also, there is a need for evaluation of cell
behavior on cement surfaces with an apatite layer formed previously on their surfaces
versus cement surfaces without any apatite layer. The changes in cell morphology with
different surfaces can be investigated using SEM analysis or time-lapse microscopy. The
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capacity for osteoblast differentiation and mineralization can be investigated by
monitoring alkaline phosphatase (ALP) and osteopontin activity using fluorescent
markers. Dalby et al. (48) investigated the initial response of primary human osteoblastlike cells (HOB) on PMMA cements containing 17.5% wt HA. They reported
significantly higher cell proliferation on HA containing cements in comparison to
PMMA cements with cell phenotype retention up to 21 days. They observed flattened
cells with small processes on PMMA samples whereas, HA surfaces showed cell
processes attaching preferentially to HA particles exposed at the cement surface rather
than the polymer matrix indicating physiological compatibility to HA. Another study by
this group investigated the effect of increasing HA incorporation into PMMA on
osteoblast adhesion and response (47) and found that focal contact formation,
cytoskeletal organization, cell proliferation and expression of phenotype increased with
increasing HA volume. Jager et al. (128) also observed similar results of increased
osteogenic potential of PMMA cement with introduction of HA particles in terms of
collagen production and ALP activity. Activity of bone mineralization markers such as
ALP and osteopontin have been seen to increase in cells cultured on compacted discs of
HA and SrHA powder (79). Hao et al. (129) evaluated osteoconduction and proliferation
of mesenchymal (MSC) and osteoblast cells (OB) on SrHA nanoparticles and observed
increased OB cell adhesion and proliferation upto 4 days in culture and higher ALP
activity with MSC cells. Thus, investigating the interaction between SrHA/SrCaHA
microspheres and osteoblasts would be worthwhile to pursue. Also, cells react
differently to rough and smooth surfaces, thus it would be worthwhile to investigate how
osteoblasts react to a cement surface that already has an apatite layer present on its
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surface which would be rougher in comparison to the cement surface without an apatite
layer.

2. Investigate the mechanical properties of SrHA/SrCaHA cements after formation of
apatite layer in SBF to replicate in vivo conditions:
Hernandez et al. (68) have characterized the compressive properties of PMMA
cements containing SrHA nanoparticles. They performed compression tests on cement
specimens stored in air at room temperature versus specimens stored in SBF for 1 month
at body temperature. They reported a decrease in mechanical properties after storage in
SBF for a month due to the plasticizing effect introduced by the absorbed water (68). A
further decrease in mechanical properties after being stored in SBF would be detrimental
for our cement formulations. Thus, measuring the mechanical properties of
SrHA/SrCaHA cements after immersion in SBF would be a meaningful investigation.
Also, measuring the residual monomer content and relating it with the mechanical
properties would provide some insight into the decrease or increase observed in the
static mechanical properties on addition of bioactive fillers.

3. Surface modification of SrHA/SrCaHA particles for better integration with PMMA
matrix:
Addition of inorganic fillers makes the bone cement brittle because of low
ductility of the fillers and the weak interface between the fillers and the cement matrix.
We have also observed this phenomenon in our study with lower flexural and fracture
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toughness properties of SrHA/SrCaHA cements resulting from agglomeration of
SrHA/SrCaHA microspheres. Thus a surface treatment of these particles could provide
improved distribution and integration with the cement matrix. HA has a significant
fraction of reactive hydroxyl groups that can be made available for grafting of organic
molecules onto the surfaces of HA particles. Hernandez et al. (74) treated SrHA
nanoparticles with MMA solution for 24 hours before introducing it into their cements
and observed immediate improvement in the mixing and injectibility of their cements as
the MMA treatment hydrophobises the surface of SrHA particles to some extent. Leong
et al. (112) also postulated that surface modification of SrHA filler with MMA will
induce matrix/filler interface integration and consequently improve mechanical
properties of bioactive cement. Dalby et al. (48) suggests grafting of HA to PMMA
using isocyanate groups that may help in maintaining mechanical properties and
incorporation of HA particles. Another possibility could be silanization of
SrHA/SrCaHA microspheres. Surface treatment by bisphosphonates is also an emerging
alternative as they are used widely as drugs for osteoporosis (112). Surface treatment of
the SrHA/SrCaHA microspheres will help prevent agglomeration as well as provide
their homogeneous dispersion in the cement.

4. Develop techniques in order to have higher concentration of SrHA/SrCaHA
microspheres available at the surface of the cements for increasing bioactive and
antibacterial response:
It has been observed that most of the bioactive filler material when added to
PMMA cements gets embedded into the matrix of the cement and is not available at the
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surface of the cement in the concentration needed for inducing bioactivity. Hernandez et
al. (74) observed better bioactivity when they polymerized their bioactive cement by
directly extruding their cement into the SBF solution at body temperature, replicating in
vivo conditions. According to them, this method leaves the bioactive particles exposed to
the medium which leads to a better bioactive response in comparison to cements cured
in air at room temperature. However, they did not discuss the mechanism that drives
these bioactive particles to the cement surface. As a preliminary study, we wanted to
investigate what would drive these particles to the surface when the cement paste is
extruded directly into a solution. We hypothesized that for the SrHA/SrCaHA particles
to be driven to the surface when the cement is injected in SBF or deionized water, they
would have to be inherently extremely hydrophilic. Thus, SrHA and SrCaHA
microsphere powder was compacted into discs (n=3) using the FTIR press as shown in
Figure 22 (a, b). The contact angles of SrHA/SrCaHA discs were measured using DROP
Image software and sessile drop technique. It was observed that both these powders
were intrinsically extremely hydrophilic and absorbed water before we could perform
any contact angle measurements. Although, initial pictures of the drop touching the
SrHA/SrCaHA discs were captured successfully as shown in Figure 22, indicating their
hydrophillicity. These preliminary observations are in line with our hypothesis.
Therefore, it would be interesting to explore this technique of extruding and
polymerizing the cement directly into SBF at body temperature and then study its
bioactive and mechanical properties in comparison to cements cured in air at room
temperature. However, one drawback that might need to be addressed with this method
would be release of monomer MMA into the SBF solution during cement
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polymerization and its sustained release in SBF with continued storage over longer time
periods. If a high concentration of monomer is present in the SBF solution, it might
affect its ability to form apatite on its surface, and the SBF solution might need to be
replaced daily.

Figure 22. (a) SrCaHA and (b) SrHA powders compressed into discs for contact angle measurements. As
can be seen from the light micrographs, the (c) SrCaHA and (d) SrHA surfaces are very hydrophyllic
showing contact angles lower than 90°. It was difficult to quantify the contact angle measurements due to
absorption of the water droplet by the sample discs.
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5. Study of the kinetics of polymerization of the η-TSBC containing SrHA/SrCaHA by
performing experiments at several curing temperatures. Understand the role of these
bioactive fillers on the kinetic parameters, setting times and polymerization exotherms
using differential scanning calorimetry (DSC) techniques.

6. Study of the shelf-life of the SrHA/SrCaHA microspheres containing η-TSBCs using
DSC techniques. Preliminary experiments, using DSC techniques previously employed
for the study of shelf-life of the STSBC formulation (130), indicated shorter shelf-life of
η-TSBC in comparison to linear STSBC. However, the large variability obtained
between the upper and lower prediction limits using this DSC technique pointed to the
need of development of a more efficient method for data acquisition and analysis of
DSC profiles.

7. Study the viability of preparation of SrHA-brush-TSBC:
Rather than using linear PMMA for the formation of composite bioactive cement,
it would be ideal to graft PMMA brushes on the surface of SrHA/SrCaHA microspheres,
thereby eliminating the use of linear PMMA, which could further improve the viscosity
of cement mixtures at higher polymer concentrations. This would also improve adhesion
between SrHA/SrCaHA microspheres and the polymer matrix. Rodrigues et al. (131)
have been successful in grafting PMMA nanospherical brushes on PMMA nanospheres
incorporated into STSBCs, through the addition of carbon-carbon double bonds on the
surface of the nanoparticles that allowed for grafting of PMMA brushes via radical
polymerization. Liu et al. (132) have also studied feasibility of grafting PMMA by using
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the reaction of isocyanate groups with the hydroxyl (OH) groups present on the surface
of HA particles. They introduced double bonds to the surface of HA via coupling
reaction of isocyanate ethyl methacrylate (ICEM) with HA followed by radical
polymerization in MMA. The same procedure could be attempted with SrHA/SrCaHA
microspheres synthesized in our study, for grafting of MMA via radical polymerization.
Details of the procedure are described in the paper by Liu and co-workers (132).

8. Study ex-vivo exothermal and mechanical properties of η-TSBC containing of
SrHA/SrCaHA microspheres:
The experimental η-TSBC performed as well as or better than the commercial
KyphX cements with respect to exothermic characteristics and mechanical properties in
an ex-vivo human cadaver study (133). Hence, investigation of polymerization
temperatures and level of mechanical augmentation of these novel bioactive η-TSBCs in
a vertebroplasty cadaver model in comparison to the performance of a commercial
cement used in the treatment of vertebral compression fractures is necessary.

9. Investigate the possibility of using η-TSBCs containing SrHA/SrCaHA microspheres as
a treatment for critical size defects in craniofacial and maxillofacial surgeries. Evaluate
the feasibility of sintering SrHA/SrCaHA microspheres to develop bioactive resorbable
scaffolds for providing bone regeneration while treating critical size defects.
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Appendices

9.1

Appendix A: Synthesis of cross-linked PMMA nanospheres

1. Materials
- Methyl methacrylate (MMA) 99% Fluka – stored in the flammable cabinet
- Ethylene glycol dimetacrylate (EGDMA) 98% Sigma – stored in the refrigerator
- Potassium Persulfate (KPS) – 99% Sigma – stored in the refrigerator
- Deionized (DI) water
- Condenser
- 1000 mL three neck flask
- 2” stir bar
- Thermometer
- Centrifuge tubes (50 mL) - Corning® 50mL centrifuge tubes
- Centrifuge bottles (250 mL Nalgene)

2. Procedure (Boiling-temperature soap-free emulsion polymerization)

- Fill a three neck flask with 400 mL DI
- Equip the three-necked flask with a condenser keeping cold water running during the entire
time of polymerization
- Add a 2” stir bar to the flask
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- Stir the solution at low speed (mark 4 in the stir plate) and turn the temperature controller on
- Mix 25 mL MMA and 6.25 mL EGDMA in a beaker. For 25% crosslinking add 8.34 mL
EGDMA instead
- Add the mixture to the water and seal the flask
- Raise the mixture to reflux and monitor the temperature (100°C). It takes about one hour and a
half for to reach the boiling point
-After the medium had boiled for 5 minutes add 0.4 g of potassium persulfate
- Let the solution mixing at low speed (mark 4) for a couple of minutes for dissolution of the
initiator.
- Monitor temperature after addition of the initiator, since the temperature tends to increase after
the mixture gets homogeneous. Keep the medium boiling during the entire period of
polymerization (100 ± 2°C)
- Increase the stir speed (mark 7.5 on the stir plate) after a milky solution has formed
- Stop the reaction after 2 hours – turn the temperature controller off
- Let the mixture stirring with the condenser assembled for another hour for cooling down

3. Drying
3.1. Centrifugation

- Add the mixture to 250 mL centrifuge bottles
- Set the centrifuge to 4500 rpm (maximum speed) and 60 minutes
- After 60 minutes of centrifugation collect the supernatant and add distilled water to the bottles
for washing of the product. Shake the bottles for mixing of the particles with water. A stick and
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white mass deposits at the bottom of the bottles after centrifugation, therefore abrupt shaking is
required to loosen the mass from the bottom
- Set the centrifuge to 4500 rpm and 60 minutes
- Collect the remaining water
- Add just a little more water and shake the bottles to loosen the mass of particles from the
bottom
- Transfer the solution to 50 mL Corning centrifuge tubes

3.2. Freeze-drying

- Place the 50 mL tubes during 24 hours in a -20°C freezer
- Transfer the tubes from the -20°C freezer to a -80°C freezer
- Keep the tubes under -80°C for at least 12 hours
- Remove the tubes from the freezer and transfer them to freeze-dryer bottles
- Remove the centrifuge tubes caps and cover them with Kim wipes
- Seal the tubes (covered with Kim wipes) with rubber bands
- Keep the particles in the freeze-dryer for at least 48 hours for complete removal of ice crystals.
If crystals are still present, let the particles drying for another couple of hours
- Subject the particles to heat treatment at 90°C for 24 hours for removal of residual initiator
- Keep the particles in a sealed flask 25 mL monomer yields about 17-18 g of crosslinked
nanospheres. The procedure can be also done with double the amount of reagents. In this case
the stir speed has to be decreased to mark 1 or 2 for the addition of the initiator to avoid
spilling of the boiling medium.
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9.2

Appendix B: Synthesis of SrHA/SrCaHA microspheres

1. Materials
-

Hexadecyl-trimethylammonium bromide (CTAB)

-

Ammonium phosphate (NH4H2PO4)

-

Strontium Nitrate (Sr(NO3)2)

-

Trisodium citrate (Cit 3-)

-

Calcium nitrate (Ca(NO3)2)

-

Deionized (DI) water

-

2” stir bar

-

Centrifuge tubes (50 ml) - Corning® 15 ml centrifuge tubes

-

Parr steel pressure vessel with 125 ml teflon bottle

-

Two 100 ml beakers

2. Procedure for synthesis of SrHA/SrCaHA microspheres
-

Fill one 100 ml with 40 ml DI water, and add a 2” stir bar to the beaker. Label it as
solution 1.

-

Fill the other 100 ml with 25 ml DI water, and add a 2” stir bar to the beaker. Label it as
solution 2.

-

For SrHA microspheres, add 0.3 g CTAB and 0.635 g strontium nitrate to solution 1 and
allow it to stir for 30 minutes

-

For SrCaHA microspheres, add 0.3 g CTAB, 0.32 g strontium nitrate, and 0.35 g calcium
nitrate to solution 1 and allow it to stir for 30 minutes.
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-

For both SrHA/SrCaHA microspheres, add 1.54 g trisodium citrate and 0.26 g
ammonium phosphate to solution 2 and allow it to stir for 30 minutes.

-

After 30 mins of stirring both the solutions, add solution 2 to the beaker of solution 1 and
let it stir for another 20-25 minutes.

-

Transfer the mixed solution into 125 ml Teflon bottle from Parr Instruments that can be
held in a stainless steel pressure vessel, seal the Teflon cup and the stainless steel
pressure vessel and keep it in the vacuum oven at 180°C for 24 hours.

-

After 24 hours, take the stainless steel vessel out of the oven, and let it cool down to room
temperature naturally.

3. Centrifugation and drying
- Once the steel vessel has cooled down, unscrew the top and remove the Teflon cup.
- You will see white particles settled to the bottom of the cup and a clear solution on the
top. In order to get all particles out, mix the solution and try to remove all particles stuck
at the bottom of the cup. You will get a milky solution.
- Transfer this solution into 15 ml conical centrifuge tubes and centrifuge for 5 mins at
1000 rpm (centrifuge is placed in the tissue culture lab, next to our lab safety hood)
- After centrifuging, remove the supernatant and add DI water to the test tubes and shake
them so the particles settled at the bottom would be resuspended in water.
- Centrifuge the tubes again for 5 mins at 1000 rpm, remove the supernatant, add DI water
and resuspend the particles in DI.
- Filter the resuspended particles using a vacuum filter and filter paper. Once all particles
are filtered, add ethanol to the funnel containing filtered particles, to clean any excess
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organic solvents. Once ethanol is filtered, remove the filter paper and leave it for drying
in the oven at 80 degrees for 24 hours.

9.3

Appendix C: Protocol by Kokubo et al. (84) for preparation of Simulated Body Fluid
(SBF)
Following tables from the Kokubo protocol shows the comparison between the
composition of human blood plasma and the as prepared SBF solution and the materials
required for the preparation of SBF solution.

Table 2. Nominal ionic concentrations of SBF in comparison to those in human blood plasma (84).
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Table 3. Order and amount of reagents required for preparing 1000 ml of SBF (84).

Procedure:
In order to prepare 1000 ml of SBF, put 700 ml of deionized water with a magnetic stirring bar
into 1000 ml plastic beaker. Set it on a heating stir plate and cover it with a parafilm. Heat the
water in the beaker to 36.5 ±1.5 °C under stirring. Dissolve only the reagents of 1st to 8th order
into the solution at 36.5 ±1.5 °C one by one in the order given in Table 3, taking care of the
indications in the following list. The reagents 9th (Tris) and 10th order (HCl) are dissolved in the
following process:


Never dissolve several reagents simultaneously. Dissolve a reagent only after the
preceding one is dissolved completely.



Since reagent CaCl2 has a great effect on precipitation of apatite and takes usually
granular form and much longer to dissolve, dissolve one granule at a time. Completely
dissolve one granule before initiation of dissolution of the next.
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Set the temperature of the solution at 36.5 ±1.5 °C. If the amount of solution is smaller
than 900 ml, add deionized water up to 900 ml in total.



Insert the electrode of the pH meter into the solution. Just before dissolving Tris, the pH
of the solution should be 2.0 ± 1.0.



With the solution temperature between 35 and 38°C, preferable to 36.5 ±1.5 °C, dissolve
reagent Tris into the solution little by little taking careful note of the pH change. After
adding a small amount of Tris, stop adding it and wait until reagent already introduced is
dissolved completely and the pH has become constant.



Then add more Tris to raise the pH gradually, until pH becomes 7.45 making sure that the
temperature is maintained at 36.5 ±1.5 °C.



When pH has risen to 7.45 ± 0.01, stop dissolving Tris, then drop 1 ml – HCl by syringe
to lower the pH to 7.42 ± 0.01, making sure that pH does not decrease below 7.40. After
the pH has fallen to 7.42 ± 0.01, dissolve the remaining Tris little by little until the pH
has risen to ≤ 7.45. Repeat this process until the whole amount of Tris is dissolved
keeping the pH within 7.42 - 7.45.



After dissolving the whole amount of Tris, adjust the temperature of the solution to 36.5
±1.5 °C and pH to 7.42.



Pour the pH adjusted solution from the beaker into a 1000 ml volumetric flask. Add
deionized water up to the marked line, put a lid on the flask and close it with the plastic
film.



After mixing the solution in the flask, keep it in water to cool it down to 20°C. After the
temperature has fallen to 20°C, add the distilled water up to the marked line.
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Prepared SBF should be preserved in plastic bottle with a lid put on tightly and kept at 410°C in a refrigerator until used. The SBF should be used within 30 days after
preparation.
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